US20140294805A1 - Novel compounds and compositions for the inhibition of nampt - Google Patents

Novel compounds and compositions for the inhibition of nampt Download PDF

Info

Publication number
US20140294805A1
US20140294805A1 US13/820,497 US201113820497A US2014294805A1 US 20140294805 A1 US20140294805 A1 US 20140294805A1 US 201113820497 A US201113820497 A US 201113820497A US 2014294805 A1 US2014294805 A1 US 2014294805A1
Authority
US
United States
Prior art keywords
phenyl
methyl
carboxamide
sulfonyl
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/820,497
Other languages
English (en)
Inventor
Kenneth W. Bair
Timm R. Baumeister
Alexandre J. Buckmelter
Karl H. Clodfelter
Peter Dragovich
Francis Gosselin
Bingsong Han
Jian Lin
Dominic J. Reynolds
Bruce Roth
Chase C. Smith
Zhongguo Wang
Po-Wai Yuen
Xiaozhang Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forma Therapeutics Inc
Valo Early Discovery Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US13/820,497 priority Critical patent/US20140294805A1/en
Publication of US20140294805A1 publication Critical patent/US20140294805A1/en
Assigned to FORMA THERAPEUTICS, INC. reassignment FORMA THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FORMA TM, LLC
Assigned to INTEGRAL EARLY DISCOVERY, INC. reassignment INTEGRAL EARLY DISCOVERY, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FORMA THERAPEUTICS, INC.
Assigned to VALO EARLY DISCOVERY, INC. reassignment VALO EARLY DISCOVERY, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: INTEGRAL EARLY DISCOVERY, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • the present invention relates to compounds and composition for inhibition of Nicotinamide phosphoribosyltransferase (“NAMPT”), their synthesis, applications and antidote.
  • NAMPT Nicotinamide phosphoribosyltransferase
  • Nicotinamide adenine dinucleotide plays fundamental roles in both cellular energy metabolism and cellular signaling.
  • energy metabolism the chemistry of the pyridine ring allows NAD to readily accept and donate electrons in hydride transfer reactions catalyzed by numerous dehydrogenases.
  • FK866 International Non-proprietary Name
  • APO866 APO866
  • FK866 FK175, or WK22.175
  • FK866 International Non-proprietary Name
  • FK866 may be used for treatment of diseases implicating deregulated apoptosis such as cancer. It has been demonstrated in the prior art that FK866 interferes with nicotinamide adenine dinucleotide (also known and hereinafter referred to as NAD) biosynthesis and induces apoptotic cell death without any DNA damaging effects.
  • NAD nicotinamide adenine dinucleotide
  • FK866 (E)-N-[4-(1-benzoylpiperidin-4-yl) butyl]-3-(pyridin-3-yl)acrylamide induces apoptosis in HepG2 cells without having primary effects on cellular energy metabolism.
  • Hasmann M Schemainda I.
  • FK866 a Highly Specific Noncompetitive Inhibitor of Nicotinamide Phosphoribosyltransferase, Represents a Novel Mechanism for Induction of Tumor Cell Apoptosis. Cancer Res 2003; 63:7436-7442.
  • FK866 In a mouse mammary carcinoma model, FK866 also induces a delay in tumor growth and an enhancement in tumor radiosensitivity accompanied with dose-dependent decreases in NAD levels, pH, and energy status. A chemosensitizing effect of FK866 has also been observed on anti-neoplastic 1-methyl-3-nitro-1-nitrosoguanidinium (MNNG)-induced cell death in THP-1 and K562 leukemia cell lines (Pogrebniak A, et al. Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents. Eur J Med Res 2006; 11:313-321. [PubMed: 17052966]).
  • MNNG anti-neoplastic 1-methyl-3-nitro-1-nitrosoguanidinium
  • GMX1777 The efficacy of GMX1777 was evaluated in xenograft models and the pharmacokinetic profile of GMX1778 and its effect on nicotinamide adenine dinucleotide cellular levels was measured by liquid chromatography/mass spectrometry. (Beauparlant P., et al. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777. Anticancer Drugs. 2009 June; 20(5):346-54).
  • GMX1777 is a water-soluble intravenously administered prodrug of GMX1778 that Gemin X in-licensed from LEO Pharma (LEO numbers: EB1627 and CHS828, respectively). These compounds and other substituted cyanoguanidines have the structures of Table 1. None of the compounds of the present invention are cyanoguanidines.
  • CHS-828 has been identified as a NAMPT inhibitor (Olesen U H, et al. Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun 2008; 367:799-804. [PubMed: 18201551]). CHS-828 has been shown to potently inhibit cell growth in a broad range of tumor cell lines, although the detailed mechanism for this inhibitory effect of CHS-828 remains undetermined (Ravaud A, et al. Phase I study and guanidine kinetics of CHS-828, a guanidine-containing compound, administered orally as a single dose every 3 weeks in solid tumors: an ECSG/EORTC study. Eur J Cancer 2005; 41:702-707. [PubMed: 15763645]). Both FK866 and CHS-828 are currently in clinical trials for cancer treatments.
  • NAMPT may also have effects on endothelium (EC) in relation to high glucose levels, oxidative stress and on aging. It is also believed that NAMPT may enable proliferating human EC to resist the oxidative stress of aging and of high glucose, and to productively use excess glucose to support replicative longevity and angiogenic activity.
  • EC endothelium
  • One aspect of this invention is the provision of compounds, compositions, kits, and antidotes for the NAMPT pathway in mammals having a compound of the Formula I:
  • each of said cycloalkyl, aryl, heterocycloalkyl, heteroaryl and alkyl is either unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, amino, aminoalkyl-, (amino)alkoxy-, —CONH 2 , —C(O)NH(alkyl), —C(O)N(alkyl) 2 , —C(O)NH(aryl), —C(O)N(aryl) 2 , —CH z F 3-z , —OCH z F 3-z , -alkyl, alkoxy-, -alkenyl, -alkynyl, aryloxy-, (alkoxyalkyl)amino-, -cycloalkyl, -heterocycloalkyl, (heterocycloalkyl)al
  • Another aspect of this invention are compounds Formula II or pharmaceutically acceptable salts thereof where X ⁇ SO 2 , and the formula is:
  • Another aspect of this invention is the provision of methods of treating a disease via the inhibition of NAMPT in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
  • Still another aspect of this invention is to provide a method for treating, preventing, inhibiting or eliminating a disease or condition in a patient by inhibiting NAMPT in said patient by administering a therapeutically effective amount of at least one compound of this disclosure, wherein said disease or condition is selected from the group consisting of cancer, ovarian cancer, breast cancer, uterine cancer, colon cancer, cervical cancer, lung cancer, prostate cancer, skin cancer, bladder cancer, pancreatic cancer, leukemia, lymphoma, Hodgkin's disease, viral infections, Human Immunodeficiency Virus, hepatitis virus, herpes virus, herpes simplex, inflammatory disorders, irritable bowel syndrome, inflammatory bowel disease, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, osteoarthritis, osteoporosis, dermatitis, atoptic dermatitis, psoriasis, systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis
  • Another preferred embodiment is a pharmaceutical formulation comprising a pharmaceutically acceptable compound of the present invention, which provides, upon administration to a human, a decrease in tumor burden and/or metastases.
  • the pharmaceutical formulation can be administered by oral means or other suitable means.
  • Yet another embodiment is a method of treating ovarian cancer in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
  • Yet another embodiment is a method of treating colon cancer in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
  • Yet another embodiment is a method of treating breast cancer in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the pharmaceutical formulation of the present invention.
  • Yet another embodiment is a method of treating leukemia in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
  • Yet another embodiment is a method of treating colon cancer before or after surgical resection and/or radiation therapy, in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
  • Yet another embodiment is a method of treating cancer before or after surgical resection and/or radiation therapy, in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention, including adjunctive therapy to treat nausea, with or without dexamethasone.
  • Yet another embodiment is a method of treating cancer before or after surgical resection and or radiation therapy, in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention, including adjunctive therapy with one or more additional therapeutic agents, or their pharmaceutically acceptable salts.
  • additional therapeutic agents include cytotoxic agents (such as for example, but not limited to, DNA interactive agents (such as cisplatin or doxorubicin)); taxanes (e.g.
  • topoisomerase II inhibitors such as etoposide
  • topoisomerase I inhibitors such as irinotecan (or CPT-11), camptostar, or topotecan
  • tubulin interacting agents such as paclitaxel, docetaxel or the epothilones
  • hormonal agents such as tamoxifen
  • thymidilate synthase inhibitors such as 5-fluorouracil or 5-FU
  • anti-metabolites such as methoxtrexate
  • alkylating agents such as temozolomide, cyclophosphamide
  • Farnesyl protein transferase inhibitors such as, SARASARTM.
  • anti-cancer also known as anti-neoplastic
  • anti-cancer agents include but are not limited to Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, oxaliplatin (ELOXATIN® from Sanofi-Synthelabo Pharmaceuticals, France), Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Ten
  • such combination products employ the compounds of this invention within the dosage range described herein (or as known to those skilled in the art) and the other pharmaceutically active agents or treatments within its dosage range.
  • the CDC2 inhibitor olomucine has been found to act synergistically with known cytotoxic agents in inducing apoptosis (J. Cell Sci., (1995) 108, 2897).
  • the compounds of the invention may also be administered sequentially with known anticancer or cytotoxic agents when a combination formulation is inappropriate.
  • the invention is not limited in the sequence of administration; compounds of the disclosed Formulas may be administered either prior to or after administration of the known anticancer or cytotoxic agent.
  • cytotoxic activity of the cyclin-dependent kinase inhibitor flavopiridol is affected by the sequence of administration with anticancer agents. Cancer Research, (1997) 57, 3375. Such techniques are within the skills of persons skilled in the art as well as attending physicians.
  • any of the aforementioned methods may be augmented by administration of fluids (such as water), loop diuretics, one or more of a chemotherapeutic or antineoplastic agent, such as leucovorin and fluorouracil, and an adjunctive chemotherapeutic agent (such as filgrastim and erythropoietin), or any combination of the foregoing.
  • fluids such as water
  • loop diuretics one or more of a chemotherapeutic or antineoplastic agent, such as leucovorin and fluorouracil
  • an adjunctive chemotherapeutic agent such as filgrastim and erythropoietin
  • Yet another embodiment is a method for administering a compound of the instant invention to a subject (e.g., a human) in need thereof by administering to the subject the pharmaceutical formulation of the present invention.
  • a subject e.g., a human
  • Yet another embodiment is a method of preparing a pharmaceutical formulation of the present invention by mixing at least one pharmaceutically acceptable compound of the present invention, and, optionally, one or more pharmaceutically acceptable additives or excipients.
  • inert, pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories.
  • the powders and tablets may be comprised of from about 5 to about 95 percent active ingredient.
  • Suitable solid carriers are known in the art, e.g., magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18th Edition, (1990), Mack Publishing Co., Easton, Pa.
  • Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration.
  • Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas, e.g. nitrogen.
  • a pharmaceutically acceptable carrier such as an inert compressed gas, e.g. nitrogen.
  • solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration.
  • liquid forms include solutions, suspensions and emulsions.
  • the compounds of the invention may also be deliverable transdermally.
  • the transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
  • the compounds of this invention may also be delivered subcutaneously.
  • the compound is administered orally or intravenously.
  • the pharmaceutical preparation is in a unit dosage form.
  • the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
  • the quantity of active compound in a unit dose of preparation may be varied or adjusted from about 1 mg to about 1000 mg, preferably from about 1 mg to about 500 mg, more preferably from about 1 mg to about 250 mg, still more preferably from about 1 mg to about 25 mg, according to the particular application.
  • the actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage regimen for a particular situation is within the skill of the art. For convenience, the total daily dosage may be divided and administered in portions during the day as required.
  • a typical recommended daily dosage regimen for oral administration can range from about 1 mg/day to about 500 mg/day, preferably 1 mg/day to 200 mg/day, in two to four divided doses.
  • Patient includes both human and animals.
  • “Mammal” means humans and other mammalian animals.
  • inhibitor refers to a molecule such as a compound, a drug, an enzyme activator or a hormone that blocks or otherwise interferes with a particular biologic activity.
  • an “effective amount” or “therapeutically effective amount” refer to a sufficient amount of the agent to provide the desired biological result. That result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system.
  • an “effective amount” for therapeutic use is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in a disease.
  • An appropriate “effective” amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.
  • the expression “effective amount” generally refers to the quantity for which the active substance has therapeutic effects.
  • the active substance is the inhibitor of the formation of Nicotinamide phosphoribosyltransferase (NAMPT).
  • the terms “treat” or “treatment” are synonymous with the term “prevent” and are meant to indicate a postponement of development of diseases, preventing the development of diseases, and/or reducing severity of such symptoms that will or are expected to develop.
  • these terms include ameliorating existing disease symptoms, preventing additional symptoms, ameliorating or preventing the underlying metabolic causes of symptoms, inhibiting the disorder or disease, e.g., arresting the development of the disorder or disease, relieving the disorder or disease, causing regression of the disorder or disease, relieving a condition caused by the disease or disorder, or stopping the symptoms of the disease or disorder.
  • pharmaceutically acceptable or “pharmacologically acceptable” is meant a material which is not biologically or otherwise substantially undesirable, i.e., the material may be administered to an individual without causing any substantially undesirable biological effects or interacting in a substantially deleterious manner with any of the components of the composition in which it is contained.
  • Exemplary salts include, but are not limited, to sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate “mesylate”, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate (i.e., 1,1′-methylene-bis(2-hydroxy-3-naphthoate)) salts.
  • sulfate citrate, acetate, oxalate, chlor
  • a pharmaceutically acceptable salt may involve the inclusion of another molecule such as an acetate ion, a succinate ion or other counter ion.
  • the counter ion may be any organic or inorganic moiety that stabilizes the charge on the parent compound.
  • a pharmaceutically acceptable salt may have more than one charged atom in its structure. Instances where multiple charged atoms are part of the pharmaceutically acceptable salt can have multiple counter ions. Hence, a pharmaceutically acceptable salt can have one or more charged atoms and/or one or more counter ion.
  • Carrier materials or what are also referred to as “excipients” include any commonly used excipients in pharmaceutics and should be selected on the basis of compatibility and the release profile properties of the desired dosage form.
  • exemplary carrier materials include, e.g., binders, suspending agents, disintegration agents, filling agents, surfactants, solubilizers, stabilizers, lubricants, wetting agents, diluents, and the like.
  • “Pharmaceutically compatible carrier materials” may comprise, e.g., acacia, gelatin, colloidal silicon dioxide, calcium glycerophosphate, calcium lactate, maltodextrin, glycerine, magnesium silicate, sodium caseinate, soy lecithin, sodium chloride, tricalcium phosphate, dipotassium phosphate, sodium stearoyl lactylate, carrageenan, monoglyceride, diglyceride, pregelatinized starch, and the like. See, e.g., Hoover, John E., Remington's Pharmaceutical Sciences , Mack Publishing Co., Easton, Pa. 1975.
  • the term “subject” encompasses mammals and non-mammals.
  • mammals include, but are not limited to, any member of the Mammalian class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like.
  • non-mammals include, but are not limited to, birds, fish and the like.
  • the mammal is a human.
  • alkyl means a straight chain or branched saturated chain having from 1 to 10 carbon atoms.
  • Representative saturated alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl, isobutyl, t-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl and the like
  • alkyl group can be unsubstituted or substituted.
  • Alkyl groups containing three or more carbon atoms may be straight, branched or cyclized.
  • lower alkyl means an alkyl having from 1 to 6 carbon atoms.
  • an “alkenyl group” includes an unbranched or branched hydrocarbon chain having one or more double bonds therein.
  • the double bond of an alkenyl group can be unconjugated or conjugated to another unsaturated group.
  • Illustrative alkenyl groups include, but are not limited to, (C 2 -C 8 ) alkenyl groups, such as ethylenyl, vinyl, allyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl, 2-ethylhexenyl, 2-propyl-2-butenyl, 4-(2-methyl-3-butene)-pentenyl and the like.
  • An alkenyl group can be unsubstituted or substituted.
  • hydroxyalkyl denotes an alkyl group as defined above wherein at least one of the hydrogen atoms of the alkyl group is replaced by a hydroxy group.
  • hydroxyalkyl include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl or n-hexyl wherein one or more hydrogen atoms are replaced by OH, as well as those hydroxyalkyl groups specifically illustrated by the examples herein below.
  • cyanoalkyl denotes an alkyl group as defined above wherein at least one of the hydrogen atoms of the alkyl group is replaced by a cyano (—CN) group.
  • alkynyl group includes an unbranched or branched hydrocarbon chain having one or more triple bonds therein.
  • the triple bond of an alkynyl group can be unconjugated or conjugated to another unsaturated group.
  • Suitable alkynyl groups include, but are not limited to, (C 2 -C 6 ) alkynyl groups, such as ethynyl, propynyl, butynyl, pentynyl, hexynyl, methylpropynyl, 4-methyl-1-butynyl, 4-propyl-2-pentynyl, 4-butyl-2-hexynyl and the like.
  • An alkynyl group can be unsubstituted or substituted.
  • haloalkyl denotes an alkyl group as defined above wherein at least one of the hydrogen atoms of the alkyl group is replaced by a halogen atom, preferably fluoro or chloro, most preferably fluoro.
  • haloalkyl include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl or n-hexyl wherein one or more hydrogen atoms are replaced by Cl, F, Br or I atom(s), as well as those haloalkyl groups specifically illustrated by the examples herein below.
  • haloalkyl groups are monofluoro-, difluoro- or trifluoro-methyl, -ethyl or -propyl, for example 3,3,3-trifluoropropyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, fluoromethyl, trifluoromethyl.
  • trifluoromethyl include CF 3 , SO 2 , and CO 2 H, respectively.
  • hydroxy means an OH group
  • alkoxy as used herein includes —O-(alkyl), wherein alkyl is defined above.
  • aminoalkyl as used herein means a group having one or more nitrogen atoms and one or more alkyl groups as defined above on the nitrogen.
  • “Aralkyl” or “arylalkyl” means an aryl-alkyl-group in which the aryl and alkyl are as previously described. Preferred aralkyls comprise a lower alkyl group. Non-limiting examples of suitable aralkyl groups include benzyl, 2-phenethyl and naphthalenylmethyl. The bond to the parent moiety is through the alkyl.
  • Heteroarylalkyl means a heteroaryl moiety as defined herein linked via an alkyl moiety (defined above) to a parent core.
  • suitable heteroaryls include 2-pyridinylmethyl, quinolinylmethyl and the like.
  • Heterocyclylalkyl means a heterocyclyl moiety as defined herein linked via an alkyl moiety (defined above) to a parent core.
  • suitable heterocyclylalkyls include piperidinylmethyl, piperazinylmethyl and the like.
  • bicyclic heteroaryl means a structure having atoms arranged in two rings fused together with at least two atoms common to each ring, and at least one of the rings being a heteroaryl ring.
  • Non limiting examples of bicyclic heteroaryl comprise bicyclic heteroaryl groups comprising 1, 2, 3 or 4 heteroatom(s) independently selected from N, S or O.
  • variable e.g., aryl, heterocycle, R 2 , etc.
  • its definition on each occurrence is independent of its definition at every other occurrence.
  • N-oxide(s) formed with a N atom member of said heteroaryl denotes a heterorayl group containing a nitrogen atom that forms a N-oxide.
  • N-oxide(s) formed with a N atom member of said heteroaryl denotes a heterorayl group containing a nitrogen atom that forms a N-oxide.
  • Illustrative and non limiting examples of such N-oxides are:
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • deuterium as used herein means a stable isotope of hydrogen having odd numbers of protons and neutrons.
  • halo as used herein means a substituent having at least one halogen selected from fluorine, chlorine, bromine, and iodine.
  • cyano as used herein means a substituent having a carbon atom joined to a nitrogen atom by a triple bond.
  • amino as used herein means a substituent containing at least one nitrogen atom.
  • aminoalkoxy as used herein means a substituent having at least one amino group and at least one alkoxy group.
  • aryloxy as used herein means a substituent of the form Ar—O— where Ar is an aryl group as defined herein.
  • methylenedioxy as used herein means a functional group with the structural formula —O—CH 2 —O— which is connected to the molecule by two chemical bonds via the oxygens.
  • alkoxyalkyl means -(alkyl)-O-(alkyl), wherein each “alkyl” is independently an alkyl group defined above.
  • (alkoxyalkyl)amino as used herein means a substituent having at least one alkoxyalkyl group as defined above and at least one amino group as defined above.
  • spiroheterocycloalkyl as used herein means a spiro group (containing no heteroatom) linked in a spiro manner to a heterocycloalkyl group.
  • a non-limiting example would be the moiety shown below:
  • heterospiroheterocycloalkyl as used herein means a spiro group (containing a hetero atom such O, N or S) linked in a spiro manner to a heterocycloalkyl group.
  • a hetero atom such O, N or S
  • a non-limiting example would be the moiety shown below:
  • Aryl means a monovalent aromatic hydrocarbon radical of 6-20 carbon atoms (C 6 -C 20 ) derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system. Some aryl groups are represented in the exemplary structures as “Ar”. Aryl includes bicyclic radicals comprising an aromatic ring fused to a saturated, partially unsaturated ring, or aromatic carbocyclic ring.
  • Typical aryl groups include, but are not limited to, radicals derived from benzene (phenyl), substituted benzenes, naphthalene, anthracene, biphenyl, indenyl, indanyl, 1,2-dihydronaphthalene, 1,2,3,4-tetrahydronaphthyl, and the like.
  • Aryl groups are optionally substituted independently with one or more substituents described herein.
  • Illustrative examples of aryl groups include, but are not limited to phenyl, naphthalene and the following moieties:
  • Illustrative substituted aryls include:
  • heteroaryl refers to a monocyclic, or fused polycyclic, aromatic heterocycle (ring structure having ring atoms selected from carbon atoms as well as nitrogen, oxygen, and/or sulfur atoms) having from 3 to 24 ring atoms per ring.
  • heteroaryl as used herein also includes a monovalent aromatic radical of a 5-, 6-, or 7-membered ring and includes fused ring systems (at least one of which is aromatic) of 5-10 atoms containing at least one heteroatom independently selected from nitrogen, oxygen, and sulfur.
  • heteroaryl groups include, but are not limited to pyridinyl, imidazolyl, imidazopyridinyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, triazolyl, thiadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiopheny
  • Heteroaryl groups may be optionally substituted independently with one or more substituents described herein.
  • 5 or 6 membered heteroaryl can be selected from the group consisting of optionally substituted pyridinyl, pyrimidinyl, thiazolyl, imidazolyl, oxazolyl, isoxazolyl, pyrazolyl, pyridinone and benzimidazolyl.
  • heteroaryl is bicyclic heteroaryl selected from benzothiazole, dihydronaphthyridine, dihydropyridopyrimidine, dihydropyrrolopyridine, furopyridine, imidazopyrazine, imidazopyrazole imidazopyridine, imidazopyrimidine, indazole, indole, isoquinoline, naphthyridine, pyrazolopyridine, pyrrolopyridine, tetrazolopyridine, tetrahydroimidazopyridine, tetrahydropyrazolopyridine, thiazolopyridine and thienopyridine.
  • heteroaryl is bicyclic heteroaryl selected from 1H-pyrazolo[3,4-b]pyridine; 1,4,6,7-Tetrahydro-pyrazolo[4,3-c]pyridine; 7,8-Dihydro-5H-pyrido[4,3-d]pyrimidine; 5,7-Dihydro-pyrrolo[3,4-b]pyridine; 7,8-Dihydro-5H-[1,6]naphthyridine; 1,4,6,7-Tetrahydro-imidazo[4,5-c]pyridine; 1,8a-dihydroimidazo[1,2-a]pyridine; thieno[3,2-c]pyridine; 1H-imidazo[1,2-b]pyrazole; 1H-pyrazolo[3,4-b]pyridine; furo[2,3-c]pyridine; 1H-pyrazolo[3,4-b]pyridine; 1H-pyrrolo[3,2-c]pyridine; thieno[[[3,2-c
  • carbon bonded heterocycles and heteroaryls are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline.
  • carbon bonded heterocycles include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, or 5-thiazolyl.
  • nitrogen bonded heterocycles and heteroaryls are bonded at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, 1H-indazole, position 2 of an isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or ⁇ -carboline.
  • nitrogen bonded heterocycles include 1-aziridyl, 1-azetedyl, 1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl, and 1-piperidinyl.
  • bicyclic heteroaryl means a structure having atoms arranged in two rings fused together with at least two atoms common to each ring, and at least one of the rings being a heteroaryl ring.
  • Illustrative examples of bicyclic heteroaryls include but are not limited to:
  • bicyclic heteroaryls include but are not limited to:
  • cycloalkyl and cycloalkenyl refers to a saturated or partially saturated, monocyclic or fused or spiro polycyclic, carbocycle having from 3 to 24 ring atoms per ring.
  • Illustrative examples of cycloalkyl and “cycloalkenyl” groups include, but are not limited to, the following moieties:
  • heterocycloalkyl refers to a monocyclic, or fused or spiro, polycyclic, ring structure that is saturated or partially saturated and has from 3 to 24 ring atoms per ring selected from C atoms and N, O, and/or S atoms.
  • ring atoms per ring selected from C atoms and N, O, and/or S atoms.
  • Illustrative examples of heterocycloalkyl and substituted heterocycloalkyl groups include, but are not limited to:
  • Numerical ranges are intended to include sequential whole numbers. For example, a range expressed as “from 0 to 4” would include 0, 1, 2, 3 and 4.
  • substituted means that the specified group or moiety bears one or more suitable substituents.
  • cycloalkyloxy refers to alkyl being the point of attachment to the core while cycloalkyl is attached to alkyl via the oxy group.
  • adjunctive chemotherapeutic agent generally refers to agents which treat, alleviate, relieve, or ameliorate the side effects of chemotherapeutic agents. Such agents include those which modify blood cell growth and maturation. Examples of adjunctive chemotherapeutic agents include, but are not limited to, filgrastim and erythropoietin. Other such adjunctive chemotherapeutic agents include those which inhibit nausea associated with administration of the chemotherapeutic agents, such as a 5-HT 3 receptor inhibitor (e.g., dolansetron, granisetron, or ondansetron), with or without dexamethasone.
  • a 5-HT 3 receptor inhibitor e.g., dolansetron, granisetron, or ondansetron
  • chemotherapeutic agent and “antineoplastic agent” generally refer to agents which treat, prevent, cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect malignancies and their metastasis.
  • agents also known as “antineoplastic agents” include, but are not limited to, prednisone, fluorouracil (e.g., 5-fluorouracil (5-FU)), anastrozole, bicalutamide, carboplatin, cisplatin, chlorambucil, cisplatin, carboplatin, docetaxel, doxorubicin, flutamide, interferon-alpha, letrozole, leuprolide, megestrol, mitomycin, oxaliplatin, paclitaxel, plicamycin (MithracinTM), tamoxifen, thiotepa, topotecan, valrubicin, vinblastine, vincristine, and any combination of any of the fluorouraci
  • NAMPT nicotinamide phosphoribosyltransferase
  • a physiologically acceptable carrier or excipient is a formulation to which the compound can be added to dissolve it or otherwise facilitate its administration.
  • the dosage forms of the present invention may contain a mixture of one or more compounds of this invention, and may include additional materials known to those skilled in the art as pharmaceutical excipients.
  • Such pharmaceutical excipients include, for example, the following: Stabilizing additives may be incorporated into the delivery agent solution. With some drugs, the presence of such additives promotes the stability and dispersibility of the agent in solution.
  • the stabilizing additives may be employed at a concentration ranging from about 0.1 and 5% (W/V), preferably about 0.5% (W/V).
  • Suitable, but non-limiting, examples of stabilizing additives include gum acacia, gelatin, methyl cellulose, polyethylene glycol, carboxylic acids and salts thereof, and polylysine.
  • the preferred stabilizing additives are gum acacia, gelatin and methyl cellulose.
  • Acidifying agents acetic acid, glacial acetic acid, citric acid, fumaric acid, hydrochloric acid, diluted hydrochloric acid, malic acid, nitric acid, phosphoric acid, diluted phosphoric acid, sulfuric acid, tartaric acid
  • Aerosol propellants butane, dichlorodifluoro-methane, dichlorotetrafluoroethane, isobutane, propane, trichloromonofluoromethane
  • Air displacements carbon dioxide, nitrogen
  • Alcohol denaturants denatonium benzoate, methyl isobutyl ketone, sucrose octacetate
  • Alkalizing agents strong ammonia solution, ammonium carbonate, diethanolamine, diisopropanolamine, potassium hydroxide, sodium bicarbonate, sodium borate, sodium carbonate, sodium hydroxide, trolamine
  • Anticaking agents see glidant
  • Antifoaming agents (dimethicone, simethi
  • the compounds of the disclosed Formulas can form salts which are also within the scope of this invention.
  • Reference to a compound of the Formulas herein is understood to include reference to salts thereof, unless otherwise indicated.
  • the term “salt(s)”, as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases.
  • zwitterions inner salts may be formed and are included within the term “salt(s)” as used herein.
  • Salts of the compounds of the Formulas may be formed, for example, by reacting a compound of Formulas with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
  • Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) and the like.
  • Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines, t-butyl amines, and salts with amino acids such as arginine, lysine and the like.
  • Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (e.g. methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g.
  • dimethyl, diethyl, and dibutyl sulfates dimethyl, diethyl, and dibutyl sulfates
  • long chain halides e.g. decyl, lauryl, and stearyl chlorides, bromides and iodides
  • aralkyl halides e.g. benzyl and phenethyl bromides
  • esters of the compounds of the invention are also considered to be part of the invention.
  • Pharmaceutically acceptable esters of the present compounds include the following groups: (1) carboxylic acid esters obtained by esterification of the hydroxy groups, in which the non-carbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl (for example, acetyl, n-propyl, t-butyl, or n-butyl), alkoxyalkyl (for example, methoxymethyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxymethyl), aryl (for example, phenyl optionally substituted with, for example, halogen, C 1-4 alkyl, or C 1-4 alkoxy or amino); (2) sulfonate esters, such as alkyl- or aralkylsulfonyl (for example, methanesulfonyl); (3) amino acid esters (for
  • Prodrugs and solvates of the compounds of the invention are also contemplated herein.
  • a discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems (1987) 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press.
  • the term “prodrug” means a compound (e.g, a drug precursor) that is transformed in vivo to yield a compound of the instant Formulas or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms (e.g., by metabolic or chemical processes), such as, for example, through hydrolysis in blood.
  • prodrugs are described by T. Higuchi and W. Stella, “Pro-drugs as Novel Delivery Systems,” Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
  • a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as, for example, (C 1 -C 8 )alkyl, (C 2 -C 12 )alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-(alkoxycarbon
  • a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as, for example, (C 1 -C 6 )alkanoyloxymethyl, 1-((C 1 -C 6 )alkanoyloxy)ethyl, 1-methyl-1-((C 1 -C 6 )alkanoyloxy)ethyl, (C 1 -C 6 )alkoxycarbonyloxymethyl, N—(C 1 -C 6 )alkoxycarbonylaminomethyl, succinoyl, (C 1 -C 6 )alkanoyl, ⁇ -amino(C 1 -C 4 )alkanyl, arylacyl and ⁇ -aminoacyl, or ⁇ -aminoacyl- ⁇ -aminoacyl, where each ⁇ -aminoacyl group is independently selected from the naturally occurring L-amino acids, P(O)
  • a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a group such as, for example, R-carbonyl, RO-carbonyl, NRR′-carbonyl where R and R′ are each independently (C 1 -C 10 )alkyl, (C 3 -C 7 ) cycloalkyl, benzyl, or R-carbonyl is a natural ⁇ -aminoacyl or natural ⁇ -aminoacyl, —C(OH)C(O)OY 1 wherein Y 1 is H, (C 1 -C 6 )alkyl or benzyl, —C(OY 2 )Y 3 wherein Y 2 is (C 1 -C 4 ) alkyl and Y 3 is (C 1 -C 6 )alkyl, carboxy(C 1 -C 6 )alkyl, amino(C 1 -C 4 )alkyl or mono
  • R-carbonyl RO-carbonyl
  • One or more compounds of the invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms.
  • “Solvate” means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. “Solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. “Hydrate” is a solvate wherein the solvent molecule is H 2 O.
  • One or more compounds of the invention may optionally be converted to a solvate.
  • Preparation of solvates is generally known.
  • M. Caira et al, J. Pharmaceutical Sci., 93(3), 601-611 (2004) describe the preparation of the solvates of the antifungal fluconazole in ethyl acetate as well as from water.
  • Similar preparations of solvates, hemisolvate, hydrates and the like are described by E. C. van Tonder et al, AAPS PharmSciTech., 5(1), article 12 (2004); and A. L. Bingham et al, Chem. Commun., 603-604 (2001).
  • a typical, non-limiting, process involves dissolving the inventive compound in desired amounts of the desired solvent (organic or water or mixtures thereof) at a higher than ambient temperature, and cooling the solution at a rate sufficient to form crystals which are then isolated by standard methods.
  • Analytical techniques such as, for example I. R. spectroscopy, show the presence of the solvent (or water) in the crystals as a solvate (or hydrate).
  • the compounds of the various Formulas may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of the various Formulas as well as mixtures thereof, including racemic mixtures, form part of the present invention.
  • the present invention embraces all geometric and positional isomers. For example, if a compound of the various Formulas incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention.
  • Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization.
  • Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers.
  • an appropriate optically active compound e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride
  • converting e.g., hydrolyzing
  • some of the compounds of the various Formulas may be atropisomers (e.g., substituted biaryls) and are considered as part of this invention.
  • Enantiomers
  • All stereoisomers for example, geometric isomers, optical isomers and the like
  • of the present compounds including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs
  • those which may exist due to asymmetric carbons on various substituents including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl).
  • salt is intended to equally apply to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the inventive compounds.
  • the present invention also embraces isotopically-labelled compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O, 31 P, 32 P, 35 S, 18 F, and 36 Cl, respectively.
  • Certain isotopically-labelled compounds of the various Formulas are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3 H) and carbon-14 (i.e., 14 C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances.
  • Isotopically labelled compounds of the various Formulas can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples hereinbelow, by substituting an appropriate isotopically labelled reagent for a non-isotopically labelled reagent.
  • Benefits of the present invention include oral administration of an optimal amount of a nicotinamide phosphoribosyltransferase biosynthesis inhibitor.
  • Benefits of the present invention include intravenous administration of an optimal amount of a nicotinamide phosphoribosyltransferase biosynthesis inhibitor.
  • Benefits of the present invention include intraperitoneal administration of an optimal amount of a nicotinamide phosphoribosyltransferase biosynthesis inhibitor.
  • Benefits of the present invention include intramural administration of an optimal amount of a nicotinamide phosphoribosyltransferase biosynthesis inhibitor.
  • Benefits of the present invention include intramuscular administration of an optimal amount of a nicotinamide phosphoribosyltransferase biosynthesis inhibitor.
  • Benefits of the present invention include subcutaneous administration of an optimal amount of a nicotinamide phosphoribosyltransferase biosynthesis inhibitor.
  • Benefits of the present invention include intra-tumor administration of an optimal amount of a nicotinamide phosphoribosyltransferase biosynthesis inhibitor.
  • Benefits of the present invention include intrathecal administration of an optimal amount of a nicotinamide phosphoribosyltransferase biosynthesis inhibitor.
  • Benefits of the present invention include subdural administration of an optimal amount of a nicotinamide phosphoribosyltransferase biosynthesis inhibitor.
  • Benefits of the present invention include periorbital administration of an optimal amount of a nicotinamide phosphoribosyltransferase biosynthesis inhibitor.
  • the present invention has important implications for the design of novel treatment strategies for patients with cancer, including leukemias and solid tumors, inflammatory diseases, osteoporosis, atherosclerosis; irritable bowel syndrome and other conditions disclosed herein or that are known to those skilled in the art.
  • An aspect of the present invention concerns compounds disclosed herein.
  • An aspect of the present invention concerns compounds which are or can be inhibitors of the formation of nicotinamide phosphoribosyltransferase.
  • An aspect of the present invention concerns the use of an inhibitor of the formation of nicotinamide phosphoribosyltransferase for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of tumors.
  • An aspect of the present invention concerns the use of an inhibitor of the formation of nicotinamide phosphoribosyltransferase for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of cancer.
  • An aspect of the present invention concerns the use of an inhibitor of the formation of nicotinamide phosphoribosyltransferase for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of cancer, where the cancer is selected from leukemia, lymphoma, ovarian cancer, breast cancer, uterine cancer, colon cancer, cervical cancer, lung cancer, prostate cancer, skin cancer, CNS cancer, bladder cancer, pancreatic cancer and Hodgkin's disease.
  • the present invention also describes one or more methods of synthesizing the compounds of the present invention.
  • the invention also describes one or more uses of the compounds of the present invention.
  • the invention also describes one or more uses of the compounds of the present invention with an adjunctive agent such as use with TNF, GCSF, or other chemotherapeutic agents
  • the invention also describes one or more uses of the pharmaceutical compositions of the present invention.
  • An aspect of the present invention concerns the use as an inhibitor of the formation of nicotinamide phosphoribosyltransferase for the preparation of a medicament used in the treatment of inflammatory diseases.
  • An aspect of the present invention concerns the use as an inhibitor of the formation of nicotinamide phosphoribosyltransferase for the preparation of a medicament used in the treatment of inflammatory diseases, such as Irritable Bowel Syndrome or Inflammatory Bowel Disease.
  • An aspect of the present invention concerns the use as an inhibitor of the formation of nicotinamide phosphoribosyltransferase for the preparation of a medicament used in the treatment of disease of the bone such as osteoporosis.
  • An aspect of the present invention concerns the use as an inhibitor of the formation of nicotinamide phosphoribosyltransferase for the preparation of a medicament used in the treatment of disease of the cardiovascular system, such as atherosclerosis.
  • An aspect of the present invention concerns the use as an inhibitor of the formation of nicotinamide phosphoribosyltransferase for the preparation of a medicament used in the treatment of disease or a condition caused by an elevated level of NAMPT.
  • Such disease or condition is one or more selected from the group consisting of cancer, ovarian cancer, breast cancer, uterine cancer, colon cancer, cervical cancer, lung cancer, prostate cancer, skin cancer, bladder cancer, pancreatic cancer, leukemia, lymphoma, Hodgkin's disease, viral infections, Human Immunodeficiency Virus, hepatitis virus, herpes virus, herpes simplex, inflammatory disorders, irritable bowel syndrome, inflammatory bowel disease, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, osteoarthritis, osteoporosis, dermatitis, atoptic dermatitis, psoriasis, systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spodylitis, graft-versus-host disease, Alzheimer's disease, cerebrovascular accident, atherosclerosis, diabetes, glomerulonephiritis, metabolic syndrome, non-small cell lung cancer, small cell
  • inventive compounds can be useful in the therapy of proliferative diseases such as, but not limited to cancer, autoimmune diseases, viral diseases, fungal diseases, neurological/neurodegenerative disorders, arthritis, inflammation, anti-proliferative (e.g., ocular retinopathy), neuronal, alopecia and cardiovascular disease.
  • proliferative diseases such as, but not limited to cancer, autoimmune diseases, viral diseases, fungal diseases, neurological/neurodegenerative disorders, arthritis, inflammation, anti-proliferative (e.g., ocular retinopathy), neuronal, alopecia and cardiovascular disease.
  • the compounds can be useful in the treatment of a variety of cancers, including (but not limited to) the following: carcinoma, including that of the bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, non-small cell lung cancer, head and neck, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma, mantle cell lymphoma, myeloma, and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and
  • the compounds of the invention may induce or inhibit apoptosis.
  • the compounds of the invention may also be useful in the chemoprevention of cancer.
  • Chemoprevention is defined as inhibiting the development of invasive cancer by either blocking the initiating mutagenic event or by blocking the progression of pre-malignant cells that have already suffered an insult or inhibiting tumor relapse.
  • a further aspect of the invention is a method of inhibiting a NAMPT pathway in an animal, said method comprising administering to said animal a pharmaceutically acceptable amount of a compound of the invention to an animal in need thereof.
  • a further aspect of the invention is a pharmaceutical formulation comprising a compound of the invention.
  • Another embodiment of the invention comprises a pharmaceutical formulation of the invention, wherein the pharmaceutical formulation, upon administration to a human, results in a decrease in tumor burden.
  • Still another embodiment of the invention is a pharmaceutical formulation, further comprising one or more of an antineoplastic agent, a chemotherapeutic agent, or an adjunctive chemotherapeutic agent.
  • the pharmaceutical formulations of the invention may further comprise a therapeutic effective amount of an adjunctive chemotherapeutic agent.
  • the adjunctive chemotherapeutic agent may be an agent which modifies blood cell growth and maturation.
  • Non-limiting examples of adjunctive chemotherapeutic agent are filgrastim, pegfilgrastim and erythropoietin.
  • the invention is also directed to a method of treating or preventing a disorder associated with excessive rate of growth of cells in a mammal comprising administering to the mammal an effective amount of the pharmaceutical formulation of the invention.
  • disorder include cancer or metastasis from malignant tumors.
  • Another aspect of the invention is a method of inhibiting tumor cell growth and rate of division in a mammal with cancer, or other disorder associated with abnormally dividing cells comprising administering to the mammal an effective amount of the pharmaceutical formulation of this invention.
  • Another embodiment of the invention is a method of treating bone pain due to excessive growth of a tumor or metastasis to bone in a mammal in need thereof comprising administering to the mammal an effective amount of the pharmaceutical formulation of this invention.
  • Still another embodiment of the invention is a method for administering a NAMPT-inhibitor-containing compound to a mammal in need thereof comprising administering to the mammal the pharmaceutical formulation of the invention.
  • the mammal is a human.
  • a further embodiment of the invention is a method of preparing a pharmaceutical formulation comprising mixing at least one pharmaceutically acceptable compound of the present invention, and, optionally, one or more pharmaceutically acceptable excipients or additives.
  • the invention is also directed to methods of synthesizing compounds of the present invention.
  • the invention is directed to compounds as described herein and pharmaceutically acceptable salts, solvates, esters, prodrugs or isomers thereof, and pharmaceutical compositions comprising one or more compounds as described herein and pharmaceutically acceptable salts or isomers thereof.
  • the invention further relates to molecules which are useful in inhibiting the enzyme nicotinamide phosphoribosyltransferase (NAMPT) and pharmaceutically acceptable salts, solvates, esters, prodrugs or isomers thereof.
  • NAMPT nicotinamide phosphoribosyltransferase
  • An aspect of this invention is the provision of compounds, compositions, kits, and antidotes for the NAMPT pathway in mammals having a compound of the Formula I:
  • each of said cycloalkyl, aryl, heterocycloalkyl, heteroaryl and alkyl is either unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, amino, aminoalkyl-, (amino)alkoxy-, —CONH 2 , —C(O)NH(alkyl), —C(O)N(alkyl) 2 , —C(O)NH(aryl), —C(O)N(aryl) 2 , —CH z F 3-z , —OCH z F 3-z , -alkyl, alkoxy-, -alkenyl, -alkynyl, aryloxy-, (alkoxyalkyl)amino-, -cycloalkyl, -heterocycloalkyl, (heterocycloalkyl)al
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is aryl, and n, m, q, t, z, Ar, X, R 4 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is heteroaryl, and n, m, q, t, z, Ar, X, R 4 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where the various moieties are independently selected, Ar is aryl, and R, n, m, q, t, z, X, R 4 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, Ar is heteroaryl, and R, n, m, q, t, z, X, R 4 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, Ar, R, n, m, q, t, z, R 4 and R 3 are as defined and X is S.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, Ar, R, n, m, q, t, z, R 4 and R 3 are as defined and X is S(O).
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, Ar, R, n, m, q, t, z, R 4 and R 3 are as defined and X is S(O 2 ).
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, Ar, R, n, m, q, t, z, R 4 and R 3 are as defined and X is O.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, Ar, R, n, m, q, t, z, R 4 and R 3 are as defined and X is C(O).
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, Ar, R, n, m, q, t, z, R 4 and R 3 are as defined and X is C(O).
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, Ar, R, n, m, q, t, z, R 4 and X are as defined and R 3 is H.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, Ar, R, n, m, q, t, z, R 4 and X are as defined and R 3 is alkyl.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, Ar, R, n, m, q, t, z, R 4 and X are as defined and R 3 is arylalkyl.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, Ar, R, n, m, q, t, z, R 3 and X are as defined and R 4 is aryl.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, Ar, R, n, m, q, t, z, R 3 and X are as defined and R 4 is heteroaryl.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, Ar, R, n, m, q, t, z, R 3 and X are as defined and R 4 is heterocycloalkyl.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is aryl, R 4 is heteroaryl, and n, m, q, t, z, Ar, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is aryl, R 4 is aryl, and n, m, q, t, z, Ar, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is heteroaryl, R 4 is heteroaryl, and n, m, q, t, z, Ar, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is heteroaryl, R 4 is aryl, and n, m, q, t, z, Ar, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is phenyl, R 1 is heteroaryl, and n, m, q, t, z, Ar, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is phenyl, R 4 is aryl, and n, m, q, t, R 1 , R 3 z, and Ar are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is heteroaryl, R 4 is phenyl, and n, m, q, t, z, Ar, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is pyrrolopyridinyl, R 4 is phenyl, and n, m, q, t, Ar, z, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is oxadiazolyl, R 4 is phenyl, and n, m, q, t, Ar, z, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is oxadiazolyl (substituted with pyridinyl), R 4 is phenyl, and n, m, q, t, z, Ar, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is pyrazolyl, R 4 is phenyl, and n, m, q, t, z, Ar, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is pyrazolyl (substituted with pyridinyl), R 4 is phenyl, and n, m, q, t, z, Ar, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is imidazolyl, R 4 is phenyl, and n, m, q, t, Ar, z, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is triazolopyridinyl, R 4 is phenyl, and n, m, q, t, z, Ar, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is naphthyridinyl, R 4 is phenyl, and n, m, q, t, z, Ar, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is tetrazolopyridinyl, R 4 is phenyl, and n, m, q, t, z, Ar, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is isoquinolinyl, R 4 is phenyl, and n, m, q, t, Ar, R 3 z, and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is quinolinyl, R 4 is phenyl, and n, m, q, t, Ar, z, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is imidazopyrazinyl, R 4 is phenyl, and n, m, q, t, z, Ar, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is quinazolinyl, R 4 is phenyl, and n, m, q, t, z, Ar, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is benzothiazolyl, R 4 is phenyl, and n, m, q, t, z, Ar, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is thienopyridinyl, R 4 is phenyl, and n, m, q, t, z, Ar, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is pyrrolopyridinyl, R 4 is thiophenyl, and n, m, q, z, t, Ar, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is oxadiazolyl, R 4 is naphthalinyl, and n, m, q, t, z, Ar, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is oxadiazolyl (substituted with pyridinyl), R 4 is quinolinyl, and n, m, q, z, t, Ar, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is pyrazolyl, R 4 is isoquinolinyl, and n, m, q, t, z, Ar, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is pyrazolyl (substituted with pyridinyl), R 4 is benzodioxinyl, and n, m, q, t, z, Ar, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is imidazolyl, R 4 is phenoxathiinyl, and n, m, q, t, z, Ar, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is pyrrolopyridinyl, R 4 is phenyl, Ar is phenyl, and n, m, q, t, z, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is oxadiazolyl, R 4 is phenyl, Ar is phenyl, and n, m, q, t, z, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I d, where the various moieties are independently selected, R is oxadiazolyl (substituted with pyridinyl), R 4 is phenyl, Ar is phenyl, and n, m, z, q, t, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is pyrazolyl, R 4 is phenyl, Ar is phenyl, and n, m, q, t, z, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is pyrazolyl (substituted with pyridinyl), R 4 is phenyl, Ar is phenyl, and n, m, q, z, t, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R is imidazolyl, R 4 is phenyl, Ar is phenyl, and n, m, q, t, z, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is triazolopyridinyl, R 4 is phenyl, Ar is phenyl, and n, m, q, t, z, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is naphthyridinyl, R 4 is phenyl, Ar is phenyl, and n, m, q, t, z, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is tetrazolopyridinyl, R 4 is phenyl, Ar is phenyl, and n, m, q, t, z, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is isoquinolinyl, R 4 is phenyl, Ar is phenyl, and n, m, q, t, z, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is quinolinyl, R 4 is phenyl, Ar is phenyl, and n, m, q, t, z, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is imidazopyrazinyl, R 4 is phenyl, Ar is phenyl, and n, m, q, t, z, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is quinazolinyl, R 4 is phenyl, Ar is phenyl, and n, m, q, t, z, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is benzothiazolyl, R 4 is phenyl, Ar is phenyl, and n, m, q, t, z, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is thienopyridinyl, R 4 is phenyl, Ar is phenyl, and n, m, q, t, z, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is pyrrolopyridinyl, R 4 is phenyl, Ar is phenyl, n is 1, m is 1, q is 0, t is 0, z is 0, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is oxadiazolyl, R 4 is phenyl, Ar is phenyl, n is 1, m is 1, q is 0, t is 0, z is 0, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is oxadiazolyl (substituted with pyridinyl), R 4 is phenyl, Ar is phenyl, n is 1, m is 1, q is 0, t is 0, z is 0, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is pyrazolyl, R 4 is phenyl, Ar is phenyl, n is 1, m is 1, q is 0, t is 0, z is 0, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where the various moieties are independently selected, R is pyrazolyl (substituted with pyridinyl), R 4 is phenyl, Ar is phenyl, n is 1, m is 1, q is 0, t is 0, z is 0, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is imidazolyl, R 4 is phenyl, Ar is phenyl, n is 1, m is 1, q is 0, t is 0, z is 0, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is triazolopyridinyl, R 4 is phenyl, Ar is phenyl, n is 1, m is 1, q is 0, t is 0, z is 0, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is naphthyridinyl, R 4 is phenyl, Ar is phenyl, n is 1, m is 1, q is 0, t is 0, z is 0, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is tetrazolopyridinyl, R 4 is phenyl, Ar is phenyl, n is 1, m is 1, q is 0, t is 0, z is 0, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is isoquinolinyl, R 4 is phenyl, Ar is phenyl, n is 1, m is 1, q is 0, t is 0, z is 0, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is quinolinyl, R 4 is phenyl, Ar is phenyl, n is 1, m is 1, q is 0, t is 0, z is 0, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is imidazopyrazinyl, R 4 is phenyl, Ar is phenyl, n is 1, m is 1, q is 0, t is 0, z is 0, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is quinazolinyl, R 4 is phenyl, Ar is phenyl, n is 1, m is 1, q is 0, t is 0, z is 0, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is benzothiazolyl, R 4 is phenyl, Ar is phenyl, n is 1, m is 1, q is 0, t is 0, z is 0, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R is thienopyridinyl, R 4 is phenyl, Ar is phenyl, n is 1, m is 1, q is 0, t is 0, z is 0, R 3 and X are as defined.
  • An embodiment of the invention is the provision of a compound of Formulas IB and IC, where the various moieties are independently selected, R is aryl, and n, A, Q and R 1 and R 2 are as defined.
  • Another embodiment of the invention is the provision of a compound of Formulas IB and IC where the various moieties are independently selected, R is heteroaryl, and n, A, Q and R 1 and R 2 are as defined.
  • Another embodiment of the invention is the provision of a compound of Formulas IB and IC, the various moieties are independently selected, R is C 3 -C 8 cycloalkyl, and n, A, Q and R 1 and R 2 are as defined.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R is C 3 -C 8 cycloalkenyl, and n, A, Q and R 1 and R 2 are as defined.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R is heterocycloalkyl, and n, A, Q and R 1 and R 2 are as defined.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R is arylalkyl, and n, A, Q and R 1 and R 2 are as defined.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R is (heteroaryl)alkyl, and n, A, Q and R 1 and R 2 are as defined.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC where the various moieties are independently selected, R is (C 3 -C 8 cycloalkyl)alkyl, and n, A, Q and R 1 and R 2 are as defined.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R is (C 3 -C 8 cycloalkenyl)alkyl, and n, A, Q and R 1 and R 2 are as defined.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R is (heterocycloalkyl)alkyl, and n, A, Q and R 1 and R 2 are as defined.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R is (aryloxy)alkyl, and n, A, Q and R 1 and R 2 are as defined.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R is (heteroaryloxy)alkyl, and n, A, Q and R 1 and R 2 are as defined.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R is (C 3 -C 8 cycloalkyloxy)alkyl, and n, A, Q and R 1 and R 2 are as defined.
  • Another embodiment of the invention is the provision of a compound of Formula IB, where the various moieties are independently selected, R is (C 3 -C 8 cycloalkenyloxy)alkyl, and n, A, Q and R 1 and R 2 are as defined.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R is (heterocycloalkyloxy)alkyl, and n, A, Q and R 1 and R 2 are as defined.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R, n, Q and R1 and R 2 are as defined and A is aryl.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where he various moieties are independently selected, R, n, Q and G are as defined and A is heteroaryl.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R, n, Q and R1 and R 2 are as defined and A is heterocycloalkyl.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R, n, Q and R1 and R 2 are as defined and A is C 3 -C 8 cycloalkyl.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where he various moieties are independently selected, R, A, Q and R1 and R 2 are as defined and n is 0.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R, A, Q and R1 and R 2 are as defined and n is 1.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R, A, Q and R1 and R 2 are as defined and n is 2.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R, A, Q and R1 and R 2 are as defined and n is 3.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R, A, Q and R1 and R 2 are as defined and n is 4.
  • Another embodiment of the invention is the provision of a compound of Formula IB, where the various moieties are independently selected, R, A, n and R1 and R 2 are as defined and Q is C(O).
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R, A, n and R 1 and R 2 are as defined and Q is S(O).
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R, A, n and R 1 and R 2 are as defined and Q is S(O 2 ).
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R, A, n and R 1 and R 2 are as defined and Q is —N(H)—S(O 2 )—.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R, A, n and R 1 and R 2 are as defined and Q is —S(O 2 )—N(H)—.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R, A, n and R 1 and R 2 are as defined and Q is —N(H)—C(O)—.
  • An embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R is phenyl, and n, A, Q and R 1 and R 2 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R is naphthyl, and n, A, Q and R 1 and R 2 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R is pyridyl, and n, A, Q and R 1 and R 2 are as defined.
  • An embodiment of the invention is the provision of a compound, where Formulas IB and IC the various moieties are independently selected, R is a pyrrolopyridinyl group, and n, A, Q and R 1 and R 2 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R is a thienopyridinyl group, and n, A, Q and R 1 and R 2 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R is an indazolyl group, and n, A, Q and R 1 and R 2 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R is a pyrazolopyridinyl group, and n, A, Q and R 1 and R 2 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R is an imidazopyridinyl group, and n, A, Q and R 1 and R 2 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R is an imidazopyrazolyl group, and n, A, Q and R 1 and R 2 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R is a tetrazolopyridinyl group, and n, A, Q and R 1 and R 2 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R is a naphthyridinyl group, and n, A, Q and R 1 and R 2 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R is a benzodiazolyl group, and n, A, Q and R 1 and R 2 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R is a benzothiazolyl group, and n, A, Q and R1 and R 2 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R is a furopyridinyl group, and n, A, Q and R1 and R 2 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula IB and I C, where the various moieties are independently selected, R is a (pyridinyloxy)methyl group, and n, A, Q and R 1 and R 2 are as defined.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R is (pyridinyl)alkyl, and n, A, Q and R 1 and R 2 are as defined.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R is (pyridinyl)ethyl, and n, A, Q and R 1 and R 2 are as defined.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R is (pyrrolopyridinyl)methyl, and n, A, Q and R1 and R 2 are as defined.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R, n, Q and R1 and R 2 are as defined and A is phenyl.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R, n, Q and R1 and R 2 are as defined and A is piperidinyl.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, R, A, n, R 2 , and Q are as defined, and R 1 is H.
  • Another embodiment of the invention is the provision of a compound of Formula IB, where the various moieties are independently selected, R, A, n, R 1 , and Q are as defined, and —R 2 is piperidinyl.
  • Another embodiment of the invention is the provision of a compound of Formula IB, where the various moieties are independently selected, R, A, n, R 1 , and Q are as defined, and —R 2 is quinolinyl.
  • Another embodiment of the invention is the provision of a compound of Formula IB, where the various moieties are independently selected, R, A, n, R 1 , and Q are as defined, R1 is H and —R 2 is morpholinyl.
  • Another embodiment of the invention is the provision of a compound of Formula IB, where the various moieties are independently selected, R, A, n, R 1 , and Q are as defined, R 1 is H and —R 2 is piperidinyl.
  • Another embodiment of the invention is the provision of a compound of Formula IB, where the various moieties are independently selected, R, A, n, R 1 , and Q are as defined, R1 is H and —R 2 is quinolinyl.
  • Another embodiment of the invention is the provision of a compound of Formula IB, where the various moieties are independently selected, R, A, n, R 1 , and Q are as defined, and —R 2 is morpholinyl.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, n, R 1 , R 2 , and Q are as defined, both A and R are aryl.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, n, R 1 , R 2 , and Q are as defined, both A and R are heteroaryl.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, n, R 1 , R 2 , and Q are as defined, R is heteroaryl and A is aryl.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, n, R 1 , R 2 , and Q are as defined, R is (heteroaryl)alkyl and A is aryl.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, n, R 1 , R 2 , and Q are as defined, R is (heteroaryloxy)alkyl and A is aryl.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, n, R 1 , R 2 , and Q are as defined, R is aryl and A is heteroaryl.
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, n, R 1 , R 2 are as defined, both A and R are aryl and Q is S(O 2 ).
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, n, R 1 , R 2 are as defined, both A and R are heteroaryl and Q is S(O 2 ).
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, n, R 1 , R 2 are as defined, A is aryl, R is heteroaryl and Q is S(O 2 ).
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, n, R 1 , R 2 are as defined, A is aryl, R is (heteroaryl)alkyl and Q is S(O 2 ).
  • Another embodiment of the invention is the provision of a compound of Formula IB and IC, where the various moieties are independently selected, n, R 1 , R 2 are as defined, A is aryl, R is (heteroaryloxy)alkyl and Q is S(O 2 ).
  • aryl, heteroaryl, heterocycloalkyl, cycloalkyl, cycloalkenyl and heterocycloalkenyl in these embodiments can be independently unsubstituted or optionally substituted or optionally fused as described earlier. Any one or more of the embodiments relating to Formula II or IIA below can be combined with one or more other embodiments for Formula II or IIA.
  • An embodiment of the invention is the provision of a compound of Formula II or II A where the various moieties are independently selected and Ar is aryl.
  • An embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected and Ar is phenyl.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected and Ar is 5 or 6 membered heteroaryl.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected and Ar is pyridine.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected and R is a bicyclic heteroaryl.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected and R is a 9 to 10 membered bicyclic heteroaryl containing 1, 2, 3, or 4 heteroatoms independently selected from N, S or O.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected and R is selected from benzothiazole, dihydronaphthyridine, dihydropyridopyrimidine, dihydropyrrolopyridine, furopyridine, imidazopyrazine, imidazopyrazole imidazopyridine, imidazopyrimidine, indazole, indole, isoquinoline, naphthyridine, pyrazolopyridine, pyrrolopyridine, tetrazolopyridine, tetrahydroimidazopyridine, tetrahydropyrazolopyridine, thiazolopyridine and thienopyridine.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected and R is selected from 1H-pyrazolo[3,4-b]pyridine; 1,4,6,7-Tetrahydro-pyrazolo[4,3-c]pyridine; 7,8-Dihydro-5H-pyrido[4,3-d]pyrimidine; 5,7-Dihydro-pyrrolo[3,4-b]pyridine; 7,8-Dihydro-5H-[1,6]naphthyridine; 1,4,6,7-Tetrahydro-imidazo[4,5-c]pyridine; 1,8a-dihydroimidazo[1,2-a]pyridine; thieno[3,2-c]pyridine; 1H-imidazo[1,2-b]pyrazole; 1H-pyrazolo[3,4-b]pyridine; furo[2,3-c]pyridine; 1H-pyrazolo[3,4-b]pyridine; 1H-pyr
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected, Ar is aryl and R is a 9 to 10 membered bicyclic heteroaryl containing 1, 2, 3, or 4 heteroatoms independently selected from N, S or O.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected, Ar is phenyl and R is a 9 to 10 membered bicyclic heteroaryl containing 1, 2, 3, or 4 heteroatoms independently selected from N, S or O.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected, Ar is phenyl and R is selected from benzothiazole, dihydronaphthyridine, dihydropyridopyrimidine, dihydropyrrolopyridine, furopyridine, imidazopyrazine, imidazopyrazole imidazopyridine, imidazopyrimidine, indazole, indole, isoquinoline, naphthyridine, pyrazolopyridine, pyrrolopyridine, tetrazolopyridine, tetrahydroimidazopyridine, tetrahydropyrazolopyridine, thiazolopyridine and thienopyridine.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected and Ar is 5 or 6 membered heteroaryl and R is a 9 to 10 membered bicyclic heteroaryl containing 1, 2, 3, or 4 heteroatoms independently selected from N, S or 0.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected, Ar is pyridine and R is a 9 to 10 membered bicyclic heteroaryl containing 1, 2, 3, or 4 heteroatoms independently selected from N, S or O.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected and R is substituted at a position adjacent to a nitrogen atom on its cycle.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected, Ar is aryl and R is substituted at a position adjacent to a nitrogen atom on its cycle.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected, Ar is phenyl and R is substituted at a position adjacent to a nitrogen atom on its cycle.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected, Ar is 5 or 6 membered heteroaryl and R is substituted at a position adjacent to a nitrogen atom on its cycle.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected, Ar is pyridine and R is substituted at a position adjacent to a nitrogen atom on its cycle.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected, R 1 is —NHR 4 and R 4 is cycloalkyl, heterocycloalkyl, aryl or heteroaryl.
  • Another embodiment of the invention is the provision of a compound of Formula III or IIIA where the various moieties are independently selected, Ar is aryl, R 1 is —NHR 4 and R 4 is cycloalkyl, heterocycloalkyl, aryl or heteroaryl.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected,
  • Ar is phenyl
  • R 1 is —NHR 4 and R 4 is cycloalkyl, heterocycloalkyl, aryl or heteroaryl.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected, Ar is 5 or 6 membered heteroaryl, R 1 is —NHR 4 and R 4 is cycloalkyl, heterocycloalkyl, aryl or heteroaryl.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected,
  • Ar is pyridine, R 1 is —NHR 4 and R 4 is cycloalkyl, heterocycloalkyl, aryl or heteroaryl.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected and R is a 9 to 10 membered bicyclic heteroaryl containing 1,2,3, or 4 heteroatoms independently selected from N, S or O, Ar is phenyl and R 1 is —NHR 4 and R 4 is cycloalkyl, heterocycloalkyl, aryl or heteroaryl.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected and R is a 9 to 10 membered bicyclic heteroaryl containing 1,2,3, or 4 heteroatoms independently selected from N, S or O, Ar is pyridine and R 1 is —NHR 4 and R 4 is cycloalkyl, heterocycloalkyl, aryl or heteroaryl.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected and R 1 is unsubstituted or substituted C 3 -C 10 cycloalkyl.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected, Ar is aryl, and R 1 is unsubstituted or substituted C 3 -C 10 cycloalkyl.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected, Ar is phenyl, and R 1 is unsubstituted or substituted C 3 -C 10 cycloalkyl.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected, Ar is 5 or 6 membered heteroaryl, and R 1 is unsubstituted or substituted C 3 -C 10 cycloalkyl.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected, Ar is pyridine, and R 1 is unsubstituted or substituted C 3 -C 10 cycloalkyl.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected and R 1 is unsubstituted or substituted aryl.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected and R 1 is unsubstituted or substituted 5 to 11 membered monocyclic or bicyclic heterocycloalkyl comprising 1,2,3, or 4 heteroatom(s) selected from N, S or O.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected, Ar is aryl and R 1 is unsubstituted or substituted 5 to 11 membered monocyclic or bicyclic heterocycloalkyl comprising 1, 2, 3, or 4 heteroatom(s) selected from N, S or O.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected, Ar is phenyl and R 1 is unsubstituted or substituted 5 to 11 membered monocyclic or bicyclic heterocycloalkyl comprising 1, 2, 3, or 4 heteroatom(s) selected from N, S or O.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected, Ar is 5 or 6 membered heteroaryl and R 1 is unsubstituted or substituted 5 to 11 membered monocyclic or bicyclic heterocycloalkyl comprising 1, 2, 3, or 4 heteroatom(s) selected from N, S or O.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected, Ar is pyridine and R 1 is unsubstituted or substituted 5 to 11 membered monocyclic or bicyclic heterocycloalkyl comprising 1, 2, 3, or 4 heteroatom(s) selected from N, S or O.
  • R 1 is unsubstituted or substituted 5 to 11 membered monocyclic or bicyclic heterocycloalkyl containing at least one N-heteroatom from which the heterocycloalkyl is attached to the rest of the compound of Formula II or IIA.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected, Ar is aryl and R 1 is unsubstituted or substituted 5 to 11 membered monocyclic or bicyclic heterocycloalkyl containing at least one N-heteroatom from which the heterocycloalkyl is attached to the rest of the compound of Formula II or IIA.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected, Ar is phenyl and R 1 is unsubstituted or substituted 5 to 11 membered monocyclic or bicyclic heterocycloalkyl containing at least one N-heteroatom from which the heterocycloalkyl is attached to the rest of the compound of Formula II or IIA.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected, Ar is 5 or 6 membered heterocyclic aryl and R 1 is unsubstituted or substituted 5 to 11 membered monocyclic or bicyclic heterocycloalkyl containing at least one N-heteroatom from which the heterocycloalkyl is attached to the rest of the compound of Formula II or IIA.
  • Another embodiment of the invention is the provision of a compound of Formula II or IIA where the various moieties are independently selected, Ar is pyridine and R 1 is unsubstituted or substituted 5 to 11 membered monocyclic or bicyclic heterocycloalkyl containing at least one N-heteroatom from which the heterocycloalkyl is attached to the rest of the compound of Formula II or IIA.
  • An embodiment of the invention are compounds of Formula IIB where R is selected from 9 to 10 membered bicyclic heteroaryl groups containing 1,2, 3 or 4 heteroatoms independently selected from N, S, and O.
  • R is selected from: benzothiazole, dihydronaphthyridine, dihydropyridopyrimidine, dihydropyrrolopyridine, furopyridine, imidazopyrazine, imidazopyrazole imidazopyridine, imidazopyrimidine, indazole, indole, isoquinoline, naphthyridine, pyrazolopyridine, pyrrolopyridine, tetrazolopyridine, tetrahydroimidazopyridine, tetrahydropyrazolopyridine, thiazolopyridine and thienopyridine.
  • R is selected from: 1H-pyrazolo[3,4-b]pyridine; 1,4,6,7-Tetrahydro-pyrazolo[4,3-c]pyridine; 7,8-Dihydro-5H-pyrido[4,3-d]pyrimidine; 5,7-Dihydro-pyrrolo[3,4-b]pyridine; 7,8-Dihydro-5H-[1,6]naphthyridine; 1,4,6,7-Tetrahydro-imidazo[4,5-c]pyridine; 1,8a-dihydroimidazo[1,2-a]pyridine; thieno[3,2-c]pyridine; 1H-imidazo[1,2-b]pyrazole; 1H-pyrazolo[3,4-b]pyridine; furo[2,3-c]pyridine; 1H-pyrazolo[3,4-b]pyridine; 1H-pyrrolo[3,2-c]pyridine; thieno[[[3,2-c]pyridine; thien
  • Another embodiment of the invention is compounds of Formula IIB where R is substituted at a position adjacent to a nitrogen atom on its cycle.
  • Still another embodiment of the invention is compounds of Formula IIB where R 1 is —NHR 4 , R 4 is cycloalkyl, heterocycloalkyl, aryl or heteroaryl.
  • Yet another embodiment of the invention is compounds of Formula IIB, where R 4 is unsubstituted or substituted cycloalkyl.
  • Another embodiment of the invention is compounds of Formula IIB, where R 4 is unsubstituted or substituted heterocycloalkyl.
  • Another embodiment of the invention is compounds of Formula IIB, where R 4 is unsubstituted or substituted aryl.
  • Yet another embodiment of the invention is compounds of Formula IIB, where R 4 is unsubstituted or substituted heteroaryl.
  • Still another embodiment of the invention is compounds of Formula IIB, where R 1 is unsubstituted or substituted C 3 -C 10 -cycloalkyl.
  • Another embodiment of the invention is compounds of Formula IIB, where R 1 is unsubstituted or substituted aryl.
  • One embodiment of the invention is compounds of Formula IIB, where R 1 is unsubstituted or substituted 5 to 10 membered monocyclic or bicyclic heteroaryl comprising 1, 2, 3 or 4 heteroatom(s) selected from N, S or O.
  • R 1 or R 4 is selected from the group consisting of: 6-methoxypyridine; 2-ethoxy-4-fluorophenyl; 3,4-difluorophenyl; 3,4-dimethoxyphenyl; 3,4-dimethoxyphenyl; 3-chloro-5-fluorophenyl; 3-fluoro-4-methoxyphenyl; 4-chloro-2-methylphenyl; 4-fluoro-2-methoxyphenyl; 4-methoxy-2,5-dimethylphenyl; 4-methylphenyl; 5-chloro-2-ethoxyphenyl; 5-fluoro-2-methoxyphenyl; 1-(3-chlorophenyl)-1H-pyrazole; 1-(4-fluorophenyl)-1H-pyrazole; 1-(propan-2-yl)-1H-pyrazole; 1,3-thiazole; 1,4-dimethyl-1H-imidazole; 1,5-di
  • R 1 is cycloalkyl, aryl or heteroaryl, wherein each of said cycloalkyl, aryl, or heteroaryl is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents which can be the same or different and are independently selected from the group consisting of: halo, hydroxy, hydroxyalkyl, cyano, alkyl, alkynyl, alkynylalkoxy, alkoxyalkyl, alkoxy, haloalkyl, haloalkoxy, —C(O)NH(alkyl), —C(O)NH(cycloalkyl), —C(O)N(alkyl) 2 , arylalkoxy-, aryloxy-, cycloalkyl, heterocycloalkyl, aryl, (heterocycloalkyl)alkyl-, (heterocycloalkyl)alkoxy-, —
  • Still another embodiment of the invention is compounds of Formula IIC, where R 1 is cycloalkyl, aryl or heteroaryl, wherein each of said cycloalkyl, aryl, or heteroaryl is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents which can be the same or different and are independently selected from the group consisting of: halo, haloalkyl and haloalkoxy.
  • Another embodiment of the invention is compounds of Formula IIB, where haloalkyl is —CH z F 3-z , —CH 2 CH z F 3-z , and z is 0, 1 or 2.
  • One embodiment of the invention is compounds of Formula IIB, where haloalkoxy is —OCH z F 3-z , and z is 0, 1 or 2.
  • Another embodiment of the invention is compounds of Formula IIB, where halo is F.
  • Another embodiment of the invention is compounds of Formula IIB, where R is 1H-pyrazolo[3,4-b]pyridine.
  • Another embodiment of the invention is compounds of Formula IIB, where R is 1,8a-dihydroimidazo[1,2-a]pyridine.
  • Compounds according to the invention may be synthesized by synthetic routes that include processes analogous to those well-known in the chemical arts, particularly in light of the description contained herein, and those for other heterocycles described in: Comprehensive Heterocyclic Chemistry II, Editors Katritzky and Rees, Elsevier, 1997, e.g. Volume 3; Liebigs Annalen der Chemie, (9):1910-16, (1985); Helvetica Chimica Acta, 41:1052-60, (1958); Arzneistoff-Forschung, 40(12):1328-31, (1990), each of which are expressly incorporated by reference.
  • Synthetic chemistry transformations and protecting group methodologies useful in synthesizing compounds according to the invention and necessary reagents and intermediates are known in the art and include, for example, those described in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley and Sons (1999); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995) and subsequent editions thereof.
  • Compounds according to the invention may be prepared singly or as compound libraries comprising at least 2, for example 5 to 1,000 compounds, or 10 to 100 compounds.
  • Libraries of compounds of Formula I may be prepared by a combinatorial ‘split and mix’ approach or by multiple parallel syntheses using either solution phase or solid phase chemistry, by procedures known to those skilled in the art.
  • a compound library comprising at least 2 compounds, or pharmaceutically acceptable salts thereof.
  • the General Procedures and Examples provide exemplary methods for preparing compounds according to the invention. Those skilled in the art will appreciate that other synthetic routes may be used to synthesize the compounds according to the invention. Although specific starting materials and reagents are depicted and discussed in the schemes, General Procedures, and Examples, other starting materials and reagents can be easily substituted to provide a variety of derivatives and/or reaction conditions. In addition, many of the exemplary compounds prepared by the described methods can be further modified in light of this disclosure using conventional chemistry well known to those skilled in the art.
  • Suitable amino-protecting groups include acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBz) and 9-fluorenylmethyleneoxycarbonyl (Fmoc).
  • BOC t-butoxycarbonyl
  • CBz benzyloxycarbonyl
  • Fmoc 9-fluorenylmethyleneoxycarbonyl
  • reaction products from one another and/or from starting materials.
  • the desired products of each step or series of steps is separated and/or purified to the desired degree of homogeneity by the techniques common in the art.
  • separations involve multiphase extraction, crystallization from a solvent or solvent mixture, distillation, sublimation, or chromatography.
  • Chromatography can involve any number of methods including, for example: reverse-phase and normal phase; size exclusion; ion exchange; high, medium and low pressure liquid chromatography methods and apparatus; small scale analytical; simulated moving bed (SMB) and preparative thin or thick layer chromatography, as well as techniques of small scale thin layer and flash chromatography.
  • SMB simulated moving bed
  • reagents selected to bind to or render otherwise separable a desired product, unreacted starting material, reaction by product, or the like.
  • reagents include adsorbents or absorbents such as activated carbon, molecular sieves, ion exchange media, or the like.
  • the reagents can be acids in the case of a basic material, bases in the case of an acidic material, binding reagents such as antibodies, binding proteins, selective chelators such as crown ethers, liquid/liquid ion extraction reagents (LIX), or the like.
  • Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as by chromatography and/or fractional crystallization.
  • Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereoisomers to the corresponding pure enantiomers.
  • an appropriate optically active compound e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride
  • converting e.g., hydrolyzing
  • some of the compounds of the present invention may be atropisomers (e.g., substituted biaryls) and are considered as part of this invention.
  • Enantiomers can also be
  • a single stereoisomer, e.g., an enantiomer, substantially free of its stereoisomer may be obtained by resolution of the racemic mixture using a method such as formation of diastereomers using optically active resolving agents (Eliel, E. and Wilen, S. “Stereochemistry of Organic Compounds,” John Wiley & Sons, Inc., New York, 1994; Lochmuller, C. H., (1975) J. Chromatogr., 113(3):283-302).
  • Racemic mixtures of chiral compounds of the invention can be separated and isolated by any suitable method, including: (1) formation of ionic, diastereomeric salts with chiral compounds and separation by fractional crystallization or other methods, (2) formation of diastereomeric compounds with chiral derivatizing reagents, separation of the diastereomers, and conversion to the pure stereoisomers, and (3) separation of the substantially pure or enriched stereoisomers directly under chiral conditions. See: “Drug Stereochemistry, Analytical Methods and Pharmacology,” Irving W. Wainer, Ed., Marcel Dekker, Inc., New York (1993).
  • diastereomeric salts can be formed by reaction of enantiomerically pure chiral bases such as brucine, quinine, ephedrine, strychnine, a-methyl-b-phenylethylamine (amphetamine), and the like with asymmetric compounds bearing acidic functionality, such as carboxylic acid and sulfonic acid.
  • the diastereomeric salts may be induced to separate by fractional crystallization or ionic chromatography.
  • addition of chiral carboxylic or sulfonic acids such as camphorsulfonic acid, tartaric acid, mandelic acid, or lactic acid can result in formation of the diastereomeric salts.
  • the substrate to be resolved is reacted with one enantiomer of a chiral compound to form a diastereomeric pair
  • a diastereomeric pair E. and Wilen, S. “Stereochemistry of Organic Compounds”, John Wiley & Sons, Inc., 1994, p. 322.
  • Diastereomeric compounds can be formed by reacting asymmetric compounds with enantiomerically pure chiral derivatizing reagents, such as menthyl derivatives, followed by separation of the diastereomers and hydrolysis to yield the pure or enriched enantiomer.
  • a method of determining optical purity involves making chiral esters, such as a menthyl ester, e.g., ( ⁇ ) menthyl chloroformate in the presence of base, or Mosher ester, a-methoxy-a-(trifluoromethyl)phenyl acetate of the racemic mixture and analyzing the 1 H NMR spectrum for the presence of the two atropisomeric enantiomers or diastereomers (Jacob III. J. Org. Chem. (1982) 47:4165).
  • Stable diastereomers of atropisomeric compounds can be separated and isolated by normal- and reverse-phase chromatography following methods for separation of atropisomeric naphthyl-isoquinolines (WO 96/15111).
  • a racemic mixture of two enantiomers can be separated by chromatography using a chiral stationary phase (“Chiral Liquid Chromatography” (1989) W. J. Lough, Ed., Chapman and Hall, New York; Okamoto, J. Chromatogr., (1990) 513:375-378).
  • Enriched or purified enantiomers can be distinguished by methods used to distinguish other chiral molecules with asymmetric carbon atoms, such as optical rotation and circular dichroism.
  • a coupling reagent such as EDCI, HATU, or HOBt
  • a base e.g.: K 2 CO 3 , Cs 2 CO 3 , NR 1 R 2 R 3 , NaOR, KOR
  • an inert solvent such as dichloromethane, N,N-dialkylformamide, N,N-dialkylacetamide, dialky
  • a coupling reagent such as EDCI, HATU, BOP, or HOBt
  • a base eg: K 2 CO 3 , Cs 2 CO 3 , NR 1 R 2 R 3 , NaOR, KOR
  • an inert solvent such as dichloromethane, N,N-dialkylformamide, N,N-dialkylacetamide, dialky
  • the compound of III present invention can also be synthesized by following the steps outlined in Scheme IV.
  • Treating II with IV in the presence of a coupling reagent such as EDCI, HATU, BOP, or HOBt, and a base eg: K 2 CO 3 , Cs 2 CO 3 , NR 1 R 2 R 3 , NaOR, KOR
  • an inert solvent such as dichloromethane, N,N-dialkylformamide, N,N-dialkylacetamide, dialkylethers, DMSO, or N-methyl-2-pyrrolidinone at temperatures ranging from ⁇ 78° C. to 200° C. gives compound V.
  • Compound V can be treated with a base such as sodium ethoxide in the present of a protonated solvent such as ethanol to afford compound VI. Treating compound VI with arylboronic acid or aryl halogens facilitated by palladium or copper to obtain the target compound III.
  • a base such as sodium ethoxide
  • a protonated solvent such as ethanol
  • Example 1C The title compound was prepared following Example 1C, substituting BOP in place of HATU, and 4-(aminomethyl)-N-(2,5-dimethoxyphenyl)benzenesulfonamide in place of 4-(aminomethyl)-N-(2-(trifluoromethoxy)phenyl)benzenesulfonamide.
  • the product was purified by PTLC.
  • Example 1A The title compound was prepared following Example 1A, substituting sodium 4-fluorobenzenesulfinate for sodium benzenesulfinate.
  • Example 1C The title compound was prepared following Example 1C, substituting (4-(benzo[d][1,3]dioxol-5-ylsulfonyl)phenyl)methanamine hydrochloride for (4-(phenylsulfonyl)phenyl)methanamine, and substituting BOP instead of HATU.
  • the title compound was purified by PTLC.
  • the title compound was prepared following Example 3C, substituting methyl 1-methyl-1H-pyrrolo[3,2-c]pyridine-2-carboxylate and (4-(phenylsulfonyl)phenyl)methanamine for methyl thieno[2,3-c]pyridine-2-carboxylate and (4-(4-fluorophenylsulfonyl)phenyl)methanamine, respectively.
  • the title compound was purified by PTLC.
  • Methyl 2,2-dichloro-2-methoxyacetate (1.585 g, 9.16 mmol) was added to a solution of pyridine-3,4-diamine (0.5 g, 4.58 mmol) and DIEA (4.80 mL, 27.5 mmol) in DCM (20 mL). The mixture was stirred at room temperature for 16 hours, whereupon EtOAc was added and the mixture washed with saturated sodium bicarbonate and brine. The organic layer was dried over MgSO 4 , filtered, concentrated, and purified by Biotage to afford the title compound.
  • the reaction was treated with aqueous ammonia and extracted with EtOAc and the organic extract was concentrated to dryness and the resulting residue was dissolved in 70% i-PrOH (0.35 mL) and 3N HCl (0.35 mL, 1.05 mmol) and was heated at 90° C. for 4 hours then concentrated to dryness.
  • the residue was treated with triethylamine (5% in ACN (v/v), 200 uL) and imidazo[1,2-a]pyridine-6-carboxylic acid (0.2 M in DMA w/10% TEA (v/v), 240 uL, 48 umol) and BOP (0.2 M DCE, 260 uL, 52 umol).
  • the solution was heated to 40° C. for 4 h then cooled to room temperature and partitioned between NaOH and EtOAc.
  • the organic layer was separated and concentrated in vacuo.
  • the crude was purified by LC/MS to afford the title compound as white solid.
  • the reaction was cooled to room temperature and 70% i-PrOH (0.35 mL) and 3N HCl (0.35 mL, 1.05 mmol) were added and was heated at 95° C. for 4 hours then concentrated to dryness.
  • the residue was treated with triethylamine (5% in ACN (v/v), 100 ⁇ L) and imidazo[1,2-a]pyridine-6-carboxylic acid (0.2 M in DMA w/10% TEA (v/v), 120 ⁇ L, 24 ⁇ mol) and BOP (0.2 M DCE, 130 ⁇ L, 26 ⁇ mol).
  • the solution was heated to 40° C. for 4 h then cooled to room temperature and partitioned between NaOH and EtOAc.
  • the organic layer was separated and deposited on a SCX-SPE cartridge which was eluted to two fractions: the 1 st with 25% MeOH/EtOAc (v/v), the 2 nd with Et3N/MeOH/EtOAc (1:1:10 v/v/v). The second fraction was concentrated to dryness and was purified by LC/MS to afford the title compound as white solid.
  • the organic layer was separated and deposited on a SCX-SPE cartridge which was eluted to two fractions: the 1 st with 25% MeOH/EtOAc (v/v), the 2 nd with ammonia in methanol (2 N). The second fraction was concentrated to dryness and was purified by LC/MS to afford the title compound as white solid.
  • Recombinant His-tagged NAMPT was produced in E. coli cells, purified over a Ni column, and further purified over a size-exclusion column by XTAL Biostructures.
  • the NAMPT enzymatic reactions were carried out in Buffer A (50 mM Hepes pH 7.5, 50 mM NaCl, 5 mM MgCl 2 , and 1 mM THP) in 96-well V-bottom plates.
  • Buffer A 50 mM Hepes pH 7.5, 50 mM NaCl, 5 mM MgCl 2 , and 1 mM THP
  • the compound titrations were performed in a separate dilution plate by serially diluting the compounds in DMSO to make a 100 ⁇ stock.
  • Buffer A (89 ⁇ L) containing 33 nM of NAMPT protein was added to 1 ⁇ L of 100 ⁇ compound plate containing controls (e.g. DMSO or blank).
  • the compound and enzyme mix was incubated for 15 minutes at room temperature, then 10 ⁇ L of 10 ⁇ substrate and co-factors in Buffer A were added to the test well to make a final concentration of 1 ⁇ M NAM, 100 ⁇ M 5-Phospho-D-ribose 1-diphosphate (PRPP), and 2.5 mM Adenosine 5′-triphosphate (ATP).
  • the reaction was allowed to proceed for 30 minutes at room temperature, then was quenched with the addition of 11 ⁇ l of a solution of formic acid and L-Cystathionine to make a final concentration of 1% formic acid and 10 ⁇ M L-Cystathionine. Background and signal strength was determined by addition (or non-addition) of a serial dilution of NMN to a pre-quenched enzyme and cofactor mix.
  • NMN and L-Cystathionine were detected using the services of Biocius Lifesciences with the RapidFire system.
  • the NMN and L-Cystathionine are bound to a graphitic carbon cartridge in 0.1% formic acid, eluted in 30% acetonitrile buffer, and injected into a Sciex 4000 mass spectrometer.
  • the components of the sample were ionized with electrospray ionization and the positive ions were detected.
  • the Q1 (parent ion) and Q3 (fragment ion) masses of NMN were 334.2 and 123.2, respectively.
  • the Q1 and Q3 for L-Cystathionine were 223.1 and 134.1, respectively.
  • the fragments are quantified and the analyzed by the following method.
  • the NMN signal is normalized to the L-Cystathionine signal by dividing the NMN signal by the L-Cystathionine signal for each well.
  • the signal from the background wells are averaged and subtracted from the test plates.
  • the compound treated cells re then assayed for % inhibition by using this formula.
  • x denotes the average signal of the compound treated wells and y denotes the average signal of the DMSO treated wells.
  • IC50s are Determined Using Excel and this Formula.
  • IC 50 10 ⁇ (LOG 10( X )+(((50 ⁇ % Inh at Cmpd Concentration 1)/( XX ⁇ YY )*(LOG 10( X ) ⁇ LOG 10( Y ))))
  • NAMPT-inhibitor compounds of this invention have IC50 values that are preferably under 1 ⁇ M, more preferably under 0.1 ⁇ M, and most preferably under 0.01 ⁇ M. Results for the compounds are provided in Table 3.
  • A2780 cells were seeded in 96-well plates at 1 ⁇ 10 3 cells/well in 180 ⁇ l of culture medium (10% FBS, 1% Pen/Strep Amphotecricin B, RPMI-1640) with and without the addition of either ⁇ -nicotinamide mononucleotide (NMN) or nicotinamide (NAM). After overnight incubation at 37° C. and 5% CO 2 , the compound titrations were performed in a separate dilution plate by serially diluting the compounds in DMSO to make a 1000 ⁇ stock. The compounds were then further diluted to 10 ⁇ final concentration in culture media, whereupon 20 ⁇ l of each dilution was added to the plated cells with controls (e.g.
  • DMSO and blank to make a final volume of 200 ⁇ L.
  • the final DMSO concentration in each well was 0.1%.
  • the plates were then incubated for 72 hours at 37° C. in a 5% CO 2 incubator. The number of viable cells was then assessed using sulforhodamine B (SRB) assay. Cells were fixed at 4° C. for 1 hour with the addition of 50 ⁇ l 30% trichloroacetic acid (TCA) to make a final concentration of 6% TCA.
  • TCA trichloroacetic acid
  • the plates were washed four times with H 2 O and allowed to dry for at least 1 hour, whereupon 100 ⁇ L of a 4% SRB in 1% acetic acid solution was added to each well and incubated at room temperature for at least 30 minutes.
  • the plates were then washed three times with 1% acetic acid, dried, and treated with 100 ⁇ L of 10 mM Tris-Base solution. The plates were then read in a microplate reader at an absorbance of 570 nm. Background was generated on a separate plate with media only.
  • x denotes the average signal of the compound-treated cells and y denotes the average signal of the DMSO-treated cells.
  • IC 50 10 ⁇ (LOG 10( X )+(((50 ⁇ % Inh at Cmpd Concentration 1)/( XX ⁇ YY )*(LOG 10( X ) ⁇ LOG 10( Y ))))
  • X denotes the compound concentration 1
  • Y denotes the compound concentration 2
  • XX denotes the % inhibition at compound concentration 1
  • YY denotes the % inhibition at compound concentration 2 (Y).
  • NAMPT Inhibition of NAMPT could be reversed by the addition of NAM or NMN.
  • the specificity of the compounds were determined via cell viability assay in the presence of the compound and either NAM or NMN. Percent inhibitions were determined using the method given above.
  • the NAMPT-inhibitor compounds of this invention have IC50 values that are preferably under 1 ⁇ M, more preferably under 0.1 ⁇ M, and most preferably under 0.01 ⁇ M. Most preferable compounds of this invention are compounds that have both the enzymatic IC50-value and the A2780 IC 50-value under 1 ⁇ M, more preferably both of the values are under 0.1 ⁇ M, and most preferably both of the values are under 0.01 ⁇ M. Results for the compounds are provided in Table 3.
  • U251 cells were seeded in 96-well plates at 1.25 ⁇ 103 cells/well in 180 ⁇ L of culture medium (10% FBS, 1% Pen/Strep Amphotecricin B, RPMI-5 1640) with and without the addition of either _-nicotinamide mononucleotide (NMN) or nicotinamide (NAM). After overnight incubation at 37° C. and 5% CO2, the compound titrations were performed in a separate dilution plate by serially diluting the compounds in DMSO to make a 1000 ⁇ stock. The compounds were then further diluted to 10 ⁇ final concentration in culture media, whereupon 20 ⁇ L of each dilution was added to the plated cells with controls (e.g.
  • DMSO and blank to make a final volume of 5 200 ⁇ L.
  • the final DMSO concentration in each well was 0.1%.
  • the plates were then incubated for 72 hours at 37° C. in a 5% CO2 incubator. The number of viable cells was then assessed using sulforhodamine B (SRB) assay. Cells were fixed at 4° C. for 1 hour with the addition of 50 ⁇ L 30% trichloroacetic acid (TCA) to make a final concentration of 6% 10 TCA.
  • TCA trichloroacetic acid
  • the plates were washed four times with H2O and allowed to dry for at least 1 hour, whereupon 100 L of a 4% SRB in 1% acetic acid solution was added to each well and incubated at room temperature for at least 30 minutes.
  • the plates were then washed three times with 1% acetic acid, dried, and treated with 100 ⁇ L of 10 mM Tris-Base solution. The plates were then read in a microplate reader at an absorbance of 570 nm. 15 Background was generated on a separate plate with media only.
  • x denotes the average signal of the compound-treated cells and y denotes the average signal of the DMSO-treated cells.
  • IC 50 10 ⁇ (LOG 10( X )+(((50 ⁇ % Inh at Cmpd Concentration 1)/( XXYY )*(LOG 10( X ) ⁇ LOG 10( Y ))))
  • X denotes the compound concentration 1
  • Y denotes the compound concentration 2
  • XX denotes the % inhibition at compound concentration 1
  • YY 30 denotes the % inhibition at compound concentration 2 (Y).
  • Table 4 below shows U251-values for some compounds.
  • mice female mice were injected s.c. with 5 ⁇ 10 6 A2780 cells (NCI) in the left flank. 10-12 days later when tumors reached 100-200 mm3 in size, mice were randomized into treatment groups of 8 mice per group including vehicle control and reference standard groups. The compounds were formulated in 60:30:10 PEG-400:D5W: Ethanol and administered p.o., at the dose volume of 10 ml/kg BID for a duration of 5 or 10 days. The dose used for efficacy was selected from the MTD (Maximum Tolerated Dose) study. Mice were weighed and tumors measured using vernier calipers every alternate day. Tumor volume was calculated according to the formula (length ⁇ width)/2. All animal work was approved by the Institutional Animal Care and Use Committee of Biological Resource Centre, Singapore.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
US13/820,497 2010-09-03 2011-09-02 Novel compounds and compositions for the inhibition of nampt Abandoned US20140294805A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/820,497 US20140294805A1 (en) 2010-09-03 2011-09-02 Novel compounds and compositions for the inhibition of nampt

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US37979610P 2010-09-03 2010-09-03
US37978910P 2010-09-03 2010-09-03
US38602310P 2010-09-24 2010-09-24
US38602810P 2010-09-24 2010-09-24
US201161475813P 2011-04-15 2011-04-15
US201161483242P 2011-05-06 2011-05-06
PCT/US2011/050321 WO2012031197A1 (en) 2010-09-03 2011-09-02 Novel compounds and compositions for the inhibition of nampt
US13/820,497 US20140294805A1 (en) 2010-09-03 2011-09-02 Novel compounds and compositions for the inhibition of nampt

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/050321 A-371-Of-International WO2012031197A1 (en) 2010-09-03 2011-09-02 Novel compounds and compositions for the inhibition of nampt

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/352,184 Continuation US10272072B2 (en) 2010-09-03 2016-11-15 Compounds and compositions for the inhibition of NAMPT

Publications (1)

Publication Number Publication Date
US20140294805A1 true US20140294805A1 (en) 2014-10-02

Family

ID=44651990

Family Applications (6)

Application Number Title Priority Date Filing Date
US13/820,497 Abandoned US20140294805A1 (en) 2010-09-03 2011-09-02 Novel compounds and compositions for the inhibition of nampt
US15/352,184 Active US10272072B2 (en) 2010-09-03 2016-11-15 Compounds and compositions for the inhibition of NAMPT
US16/212,360 Active US10456382B2 (en) 2010-09-03 2018-12-06 Compounds and compositions for the inhibition of NAMPT
US16/538,208 Active US10772874B2 (en) 2010-09-03 2019-08-12 Compounds and compositions for the inhibition of NAMPT
US17/018,196 Active 2031-12-12 US11547701B2 (en) 2010-09-03 2020-09-11 Compounds and compositions for the inhibition of NAMPT
US18/073,768 Pending US20230346753A1 (en) 2010-09-03 2022-12-02 Novel compounds and compositions for the inhibition of nampt

Family Applications After (5)

Application Number Title Priority Date Filing Date
US15/352,184 Active US10272072B2 (en) 2010-09-03 2016-11-15 Compounds and compositions for the inhibition of NAMPT
US16/212,360 Active US10456382B2 (en) 2010-09-03 2018-12-06 Compounds and compositions for the inhibition of NAMPT
US16/538,208 Active US10772874B2 (en) 2010-09-03 2019-08-12 Compounds and compositions for the inhibition of NAMPT
US17/018,196 Active 2031-12-12 US11547701B2 (en) 2010-09-03 2020-09-11 Compounds and compositions for the inhibition of NAMPT
US18/073,768 Pending US20230346753A1 (en) 2010-09-03 2022-12-02 Novel compounds and compositions for the inhibition of nampt

Country Status (20)

Country Link
US (6) US20140294805A1 (zh)
EP (1) EP2611804A1 (zh)
JP (2) JP5881704B2 (zh)
KR (1) KR20130114119A (zh)
CN (1) CN103384668B (zh)
AR (1) AR082885A1 (zh)
AU (1) AU2011295725B2 (zh)
BR (1) BR112013004773B1 (zh)
CA (1) CA2810038A1 (zh)
CR (1) CR20130104A (zh)
EC (1) ECSP13012540A (zh)
IN (1) IN2013CN02463A (zh)
MX (1) MX347889B (zh)
MY (1) MY190351A (zh)
NZ (1) NZ607638A (zh)
PE (1) PE20140011A1 (zh)
RU (1) RU2617988C2 (zh)
SG (1) SG188367A1 (zh)
WO (1) WO2012031197A1 (zh)
ZA (1) ZA201301329B (zh)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140248240A1 (en) * 2011-05-09 2014-09-04 Kenneth W. Bair Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt)
US20160031880A1 (en) * 2010-11-15 2016-02-04 Abbvie Inc. Nampt and Rock Inhibitors
US10272072B2 (en) 2010-09-03 2019-04-30 Forma Tm, Llc Compounds and compositions for the inhibition of NAMPT
US10316040B2 (en) 2015-10-16 2019-06-11 Eisai R&D Management Co., Ltd. EP4 antagonists
US10329275B2 (en) 2010-09-03 2019-06-25 Forma Tm, Llc Compounds and compositions for the inhibition of NAMPT
US10392416B2 (en) 2015-10-02 2019-08-27 Metro International Biotech, Llc Crystal forms of beta-nicotinamide mononucleotide
US10548913B2 (en) 2015-08-05 2020-02-04 Metro International Biotech, Llc Nicotinamide mononucleotide derivatives and their uses
US10618927B1 (en) 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
US10696692B2 (en) 2012-03-02 2020-06-30 Forma Tm, Llc Amido-benzyl sulfone and sulfoxide derivates
US10730889B2 (en) 2012-03-02 2020-08-04 Forma Tm, Llc Amido spirocyclic amide and sulfonamide derivatives
US11180521B2 (en) 2018-01-30 2021-11-23 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
CN114845722A (zh) * 2019-11-28 2022-08-02 努瓦米德公司 化合物在预防和/或治疗强直性脊柱炎中的应用和相应的组合物
US11787830B2 (en) 2021-05-27 2023-10-17 Metro International Biotech, Llc Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2817093A1 (en) * 2010-11-15 2012-05-24 Abbvie Inc. Nampt inhibitors
WO2013130943A1 (en) * 2012-03-02 2013-09-06 Genentech, Inc. Alkyl-and di-substituted amido-benzyl sulfonamide derivatives
JP2015508785A (ja) * 2012-03-02 2015-03-23 ジェネンテック， インコーポレイテッド ピリジニル及びピリミジニルスルホキシド及びスルホン誘導体
WO2013127268A1 (en) * 2012-03-02 2013-09-06 Genentech,Inc. Amido-benzyl sulfone and sulfonamide derivatives
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
US9193723B2 (en) 2012-05-11 2015-11-24 Abbvie Inc. NAMPT inhibitors
KR101684955B1 (ko) 2012-07-23 2016-12-12 주식회사유한양행 퓨란-함유 융합 고리 화합물 또는 그의 염 및 이를 포함하는 약학 조성물
WO2014111871A1 (en) 2013-01-17 2014-07-24 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
EA031804B1 (ru) 2014-02-03 2019-02-28 Вайтаи Фармасьютиклз, Инк. Дигидропирролопиридиновые ингибиторы ror-гамма
US10144742B2 (en) 2014-04-18 2018-12-04 Millennium Pharmaceuticals, Inc. Quinoxaline compounds and uses thereof
JP2017521426A (ja) 2014-07-23 2017-08-03 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ Ｎａｍｐｔ抑制物質としての４，５−ジヒドロイソオキサゾール誘導体
JP6564029B2 (ja) 2014-10-14 2019-08-21 ヴァイティー ファーマシューティカルズ，エルエルシー Ｒｏｒ−ガンマのジヒドロピロロピリジン阻害剤
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
WO2016118565A1 (en) 2015-01-20 2016-07-28 Millennium Pharmaceuticals, Inc. Quinazoline and quinoline compounds and uses thereof
ES2856931T3 (es) 2015-08-05 2021-09-28 Vitae Pharmaceuticals Llc Moduladores de ROR-gamma
EP3377482B1 (en) 2015-11-20 2021-05-12 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
CN108779104B (zh) * 2016-03-17 2021-04-13 将军治疗有限公司 用于抑制烟酰胺磷酸核糖转移酶的新化合物和包含它的组合物
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
KR101869794B1 (ko) * 2016-07-20 2018-06-21 연세대학교 산학협력단 내성암, 재발암 또는 전이암의 예방 또는 치료용 약학 조성물
WO2018030550A1 (en) 2016-08-09 2018-02-15 Takeda Pharmaceutical Company Limited Heterocyclic compounds with an ror(gamma)t modulating activity
BR112019006778A2 (pt) 2016-10-18 2019-10-15 Seattle Genetics Inc Composição de conjugado de aglutinante-fármaco, formulação, uso da mesma, método para preparar uma composição ou composto de conjugado de aglutinantefármaco,e, composto de ligante de fármaco
WO2018086703A1 (en) 2016-11-11 2018-05-17 Bayer Pharma Aktiengesellschaft Dihydropyridazinones substituted with phenylureas
KR20190141181A (ko) 2017-04-27 2019-12-23 시애틀 지네틱스, 인크. 사차화된 니코틴아미드 아데닌 다이뉴클레오타이드 구제 경로 억제제 콘쥬게이트
US10471045B2 (en) * 2017-07-21 2019-11-12 The University Of Hong Kong Compounds and methods for the treatment of microbial infections
AR112461A1 (es) 2017-07-24 2019-10-30 Vitae Pharmaceuticals Inc PROCESOS PARA LA PRODUCCIÓN DE SALES Y FORMAS CRISTALINAS DE INHIBIDORES DE RORg
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CN107903246A (zh) * 2017-12-22 2018-04-13 田立志 一种磺酰胺衍生物、制备方法及其抗肿瘤中的应用
CN107814788B (zh) * 2017-12-22 2018-08-31 博奥信生物技术（南京）有限公司 一种磺酰胺衍生物、制备方法及其作为nampt抑制剂的应用
CN107987060A (zh) * 2017-12-22 2018-05-04 田立志 一种磺酰胺衍生物及其作为nampt抑制剂在抗肿瘤药物中的应用
CN107915721A (zh) * 2017-12-22 2018-04-17 田立志 一种磺酰胺衍生物及其作为烟酰胺磷酸核糖转移酶抑制剂在抗肿瘤药物中的应用
KR101937126B1 (ko) * 2018-06-15 2019-01-10 연세대학교 산학협력단 내성암, 재발암 또는 전이암의 예방 또는 치료용 약학 조성물
KR102104949B1 (ko) * 2018-06-20 2020-04-27 주식회사 체크메이트테라퓨틱스 Naprt 음성 암 치료용 신규 화합물 및 이를 포함하는 조성물
CN112601745B (zh) * 2018-10-24 2023-06-27 上海和誉生物医药科技有限公司 一种氮杂芳基酰胺衍生物及其制备方法和应用
US20230066268A1 (en) * 2019-12-18 2023-03-02 Merck Sharp & Dohme Llc Indazole derivatives and methods of use thereof for the treatment of herpes viruses
CN113278409B (zh) * 2021-06-22 2022-04-29 西南石油大学 一种高温酸化缓蚀剂
WO2024091450A1 (en) * 2022-10-24 2024-05-02 The Regents Of The University Of California Compounds and methods for treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013127268A1 (en) * 2012-03-02 2013-09-06 Genentech,Inc. Amido-benzyl sulfone and sulfonamide derivatives

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3627768A (en) * 1969-06-24 1971-12-14 Schering Ag Isoxazolecarbonamidobenzene-sulfonamides
US4031068A (en) 1976-07-26 1977-06-21 Uniroyal Inc. Non-migratory sulfonyl azide antioxidants
US5264448A (en) 1989-04-19 1993-11-23 Sumitomo Chemical Company, Limited Amide compound and its production and use
US5206259A (en) * 1989-04-19 1993-04-27 Sumitomo Chemical Company, Limited Amide compound and its production and use
US5380718A (en) 1990-05-15 1995-01-10 E. I. Du Pont De Nemours And Company Arthropodicidal fused tetrahydropyridazines
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
DE19624704A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalkansäureamide
US6362183B1 (en) 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
DE19756212A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
DE19756261A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
DE19756235A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
DE19756236A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
US6706729B1 (en) 1998-06-19 2004-03-16 The United States Of America As Represented By The Department Of Health And Human Services Thiolesters and uses thereof
EP1031564A1 (en) 1999-02-26 2000-08-30 Klinge Pharma GmbH Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
AU775625B2 (en) 1999-08-27 2004-08-05 Sugen, Inc. Phosphate mimics and methods of treatment using phosphatase inhibitors
ATE344237T1 (de) * 1999-09-04 2006-11-15 Astrazeneca Ab Hydroxyacetamidobenzolsulfonamidderivate
EP1088822A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl hydrazide derivatives
WO2001068652A1 (en) 2000-03-17 2001-09-20 Novo Nordisk A/S Condensed imidazoles as histamine h3 receptor ligands
EP1193256A1 (en) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active benzsulfonamide derivatives as inhibitors of JNK proteins
AU2590202A (en) 2000-12-01 2002-06-11 Targent Inc Methods for contemporaneous administration of levamisole and 5-fluorouracil
US6982274B2 (en) 2001-04-16 2006-01-03 Eisai Co., Ltd. 1H-indazole compound
US20030105144A1 (en) * 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
EP1348434A1 (en) 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
US7491827B2 (en) 2002-12-23 2009-02-17 Millennium Pharmaceuticals, Inc. Aryl sulfonamides useful as inhibitors of chemokine receptor activity
EP1590327A1 (en) 2002-12-23 2005-11-02 Millennium Pharmaceuticals, Inc. Ccr8 inhibitors
TW200510311A (en) 2002-12-23 2005-03-16 Millennium Pharm Inc CCr8 inhibitors
CA2536313A1 (en) 2003-08-22 2005-03-03 Takeda Pharmaceutical Company Limited Fused pyrimidine derivative and use thereof
CA2563180C (en) * 2004-04-23 2013-08-06 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
DE102004028862A1 (de) 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
JP2008524294A (ja) * 2004-12-21 2008-07-10 デブジェン エヌブイ イオンチャンネル、特にＫｖファミリーのイオンチャンネルと相互作用する化合物
US7888374B2 (en) * 2005-01-28 2011-02-15 Abbott Laboratories Inhibitors of c-jun N-terminal kinases
KR20080050468A (ko) 2005-10-06 2008-06-05 사노피-아벤티스 Ｎ-[1,3,4]-티아디아졸-2-일-벤젠 설폰아미드, 이의 제조방법 및 약제로서의 이의 용도
WO2008026018A1 (en) 2006-09-01 2008-03-06 Topotarget Switzerland Sa New method for the treatment of inflammatory diseases
WO2008061109A2 (en) 2006-11-15 2008-05-22 Forest Laboratories Holdings Limited Indazole derivatives useful as melanin concentrating receptor ligands
EP2132178B1 (en) * 2006-12-20 2015-08-19 Merck Sharp & Dohme Corp. Jnk inhibitors
EP2125778A1 (en) * 2006-12-22 2009-12-02 Millennium Pharmaceuticals, Inc. Certain pyrazoline derivatives with kinase inhibitory activity
US8450348B2 (en) 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
WO2009134666A1 (en) 2008-04-29 2009-11-05 Boehringer Ingelheim International Gmbh Indazole compounds as ccr1 receptor antagonists
GB0808282D0 (en) * 2008-05-07 2008-06-11 Medical Res Council Compounds for use in stabilizing p53 mutants
AU2009296839A1 (en) * 2008-09-26 2010-04-01 Boehringer Ingelheim International Gmbh Azaindazole compounds as CCR1 receptor antagonists
WO2010096722A1 (en) 2009-02-20 2010-08-26 Takeda Pharmaceutical Company Limited 3-oxo-2, 3-dihydro- [1,2, 4] triazolo [4, 3-a]pyridines as soluble epoxide hydrolase (seh) inhibitors
US8415333B2 (en) * 2009-02-24 2013-04-09 Respiratorious Ab Bronchodilating diazaheteroaryls
FR2943669B1 (fr) 2009-03-24 2011-05-06 Sanofi Aventis Derives de nicotinamide,leur preparation et leur application en therapeutique
FR2943675A1 (fr) 2009-03-24 2010-10-01 Sanofi Aventis Composes anticancereux, leur preparation et leur application en therapeutique
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
KR20140020823A (ko) 2010-09-03 2014-02-19 포르마 티엠, 엘엘씨. Ｎａｍｐｔ의 억제를 위한 구아니딘 화합물 및 조성물
EP2611804A1 (en) 2010-09-03 2013-07-10 Forma TM, LLC. Novel compounds and compositions for the inhibition of nampt
RU2617424C2 (ru) 2010-09-03 2017-04-25 ФОРМА ТиЭм, ЭлЭлСИ Новые соединения и композиции для ингибирования nampt
WO2012061926A1 (en) 2010-11-08 2012-05-18 Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
TW201245152A (en) 2011-05-04 2012-11-16 Forma Tm Llc Novel compounds and compositions for the inhibition of NAMPT
JP5872027B2 (ja) 2011-05-09 2016-03-01 フォーマ ティーエム， エルエルシー． ニコチンアミドホスホリボシルトランスフェラーゼ（ｎａｍｐｔ）を阻害するためのピペリジン誘導体および組成物
US9493481B2 (en) 2012-02-23 2016-11-15 Vanderbilt University Substituted 5-aminothieno[2,3—C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4
WO2013130943A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Alkyl-and di-substituted amido-benzyl sulfonamide derivatives
WO2013130935A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Amido-benzyl sulfoxide derivatives
JP2015508785A (ja) 2012-03-02 2015-03-23 ジェネンテック， インコーポレイテッド ピリジニル及びピリミジニルスルホキシド及びスルホン誘導体
EP2820008B1 (en) 2012-03-02 2016-12-14 Genentech, Inc. Amido spirocyclic amide and sulfonamide derivatives
EP2820018A4 (en) * 2012-03-02 2015-09-02 Genentech Inc AMIDO-BENZYLIC SULFOXIDE AND SULFONES DERIVATIVES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013127268A1 (en) * 2012-03-02 2013-09-06 Genentech,Inc. Amido-benzyl sulfone and sulfonamide derivatives

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Cook et al. "Preparation of aryla....." CA152:429699 (2010) *
Feng et al. "Preparation of oxodihydro....." CA153:359036 (2010) *
Improper Markush, Fed. Reg. 76(27) p.7162-7175, slide 1, 64-67 (2011) *
Lindsley et al. "Preparation of substituted....." CA159:426465 (2013) *
Pajouhesh et al. "Preparation of arylsulfone......" CA156:666176 (2012) *
Petry et al. "Azolopyridin-3-one....." CA156:74422 (2011) *

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10456382B2 (en) 2010-09-03 2019-10-29 Forma Tm, Llc Compounds and compositions for the inhibition of NAMPT
US10772874B2 (en) 2010-09-03 2020-09-15 Forma Tm, Llc Compounds and compositions for the inhibition of NAMPT
US10647695B2 (en) 2010-09-03 2020-05-12 Forma Tm, Llc Compounds and compositions for the inhibition of NAMPT
US11279687B2 (en) 2010-09-03 2022-03-22 Valo Health, Inc. Compounds and compositions for the inhibition of NAMPT
US10272072B2 (en) 2010-09-03 2019-04-30 Forma Tm, Llc Compounds and compositions for the inhibition of NAMPT
US11547701B2 (en) 2010-09-03 2023-01-10 Valo Health, Inc. Compounds and compositions for the inhibition of NAMPT
US10329275B2 (en) 2010-09-03 2019-06-25 Forma Tm, Llc Compounds and compositions for the inhibition of NAMPT
US10093624B2 (en) * 2010-11-15 2018-10-09 Abbvie Inc. NAMPT and ROCK inhibitors
US20160031880A1 (en) * 2010-11-15 2016-02-04 Abbvie Inc. Nampt and Rock Inhibitors
US11479564B2 (en) 2011-05-09 2022-10-25 Valo Health, Inc. Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)
US20140248240A1 (en) * 2011-05-09 2014-09-04 Kenneth W. Bair Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt)
US9555039B2 (en) * 2011-05-09 2017-01-31 Forma Tm, Llc. Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)
US11485745B2 (en) 2012-03-02 2022-11-01 Valo Health, Inc. Amido spirocyclic amide and sulfonamide derivatives
US10696692B2 (en) 2012-03-02 2020-06-30 Forma Tm, Llc Amido-benzyl sulfone and sulfoxide derivates
US10730889B2 (en) 2012-03-02 2020-08-04 Forma Tm, Llc Amido spirocyclic amide and sulfonamide derivatives
US11464796B2 (en) 2015-08-05 2022-10-11 Metro International Biotech, Llc Nicotinamide mononucleotide derivatives and their uses
US11878027B2 (en) 2015-08-05 2024-01-23 Metro International Biotech, Llc Nicotinamide mononucleotide derivatives and their uses
US10548913B2 (en) 2015-08-05 2020-02-04 Metro International Biotech, Llc Nicotinamide mononucleotide derivatives and their uses
US11059847B2 (en) 2015-10-02 2021-07-13 Metro International Biotech, Llc Crystal forms of β-nicotinamide mononucleotide
US10392416B2 (en) 2015-10-02 2019-08-27 Metro International Biotech, Llc Crystal forms of beta-nicotinamide mononucleotide
US10941148B2 (en) 2015-10-16 2021-03-09 Eisai R&D Management Co., Ltd. EP4 antagonists
US11434246B2 (en) 2015-10-16 2022-09-06 Eisai R&D Management Co., Ltd. EP4 antagonists
US10316040B2 (en) 2015-10-16 2019-06-11 Eisai R&D Management Co., Ltd. EP4 antagonists
US11180521B2 (en) 2018-01-30 2021-11-23 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
US10618927B1 (en) 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
CN114845722A (zh) * 2019-11-28 2022-08-02 努瓦米德公司 化合物在预防和/或治疗强直性脊柱炎中的应用和相应的组合物
US11787830B2 (en) 2021-05-27 2023-10-17 Metro International Biotech, Llc Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use
US11952396B1 (en) 2021-05-27 2024-04-09 Metro International Biotech, Llc Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use

Also Published As

Publication number Publication date
US10772874B2 (en) 2020-09-15
US11547701B2 (en) 2023-01-10
EP2611804A1 (en) 2013-07-10
ECSP13012540A (es) 2013-06-28
JP2016138103A (ja) 2016-08-04
MY190351A (en) 2022-04-15
RU2013114846A (ru) 2014-10-10
CN103384668A (zh) 2013-11-06
CA2810038A1 (en) 2012-03-08
BR112013004773A2 (pt) 2017-09-19
US20190388405A1 (en) 2019-12-26
US20190105307A1 (en) 2019-04-11
WO2012031197A1 (en) 2012-03-08
AR082885A1 (es) 2013-01-16
US10272072B2 (en) 2019-04-30
MX2013002461A (es) 2013-07-29
AU2011295725B2 (en) 2015-03-26
ZA201301329B (en) 2014-04-30
NZ607638A (en) 2015-04-24
RU2617988C2 (ru) 2017-05-02
CR20130104A (es) 2013-06-27
US20210244717A1 (en) 2021-08-12
JP5881704B2 (ja) 2016-03-09
JP2013536869A (ja) 2013-09-26
KR20130114119A (ko) 2013-10-16
IN2013CN02463A (zh) 2015-08-07
BR112013004773B1 (pt) 2022-05-31
CN103384668B (zh) 2017-05-31
AU2011295725A1 (en) 2013-03-28
MX347889B (es) 2017-05-17
PE20140011A1 (es) 2014-01-31
SG188367A1 (en) 2013-04-30
US10456382B2 (en) 2019-10-29
US20170368039A1 (en) 2017-12-28
US20230346753A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
US11547701B2 (en) Compounds and compositions for the inhibition of NAMPT
US11479564B2 (en) Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)
AU2011367222B2 (en) Novel compounds and compositions for the inhibition of NAMPT
EP2820017B1 (en) Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives
WO2013130943A1 (en) Alkyl-and di-substituted amido-benzyl sulfonamide derivatives
JP2015508784A (ja) アミド−ベンジルスルホン及びスルホキシド誘導体
WO2013130935A1 (en) Amido-benzyl sulfoxide derivatives

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE

AS Assignment

Owner name: FORMA THERAPEUTICS, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FORMA TM, LLC;REEL/FRAME:053387/0440

Effective date: 20200701

AS Assignment

Owner name: INTEGRAL EARLY DISCOVERY, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FORMA THERAPEUTICS, INC.;REEL/FRAME:053402/0298

Effective date: 20200430

AS Assignment

Owner name: VALO EARLY DISCOVERY, INC., MASSACHUSETTS

Free format text: CHANGE OF NAME;ASSIGNOR:INTEGRAL EARLY DISCOVERY, INC.;REEL/FRAME:053787/0138

Effective date: 20200911